{"gene":"TREM2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2015,"finding":"TREM2 directly senses a broad array of anionic and zwitterionic lipids associated with fibrillar Aβ and damaged-neuron membranes, triggering intracellular protein tyrosine phosphorylation; the R47H mutation impairs this lipid detection. In the 5XFAD mouse model, TREM2 deficiency and haploinsufficiency augment Aβ accumulation due to failure of microglia to cluster around plaques and increased microglial apoptosis.","method":"Lipid-binding assays, 5XFAD mouse model (knockout and haploinsufficient), microglial survival and clustering assays, intracellular phosphorylation readouts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (lipid-binding assays, in vivo mouse model, phosphorylation assays) in a single rigorous study; foundational mechanism paper replicated broadly","pmids":["25728668"],"is_preprint":false},{"year":2016,"finding":"TREM2 binds apolipoproteins (including APOE and CLU/APOJ) and lipoprotein particles (including LDL), identified by unbiased protein microarray screen. Disease-associated TREM2 mutations abolish or reduce this binding. TREM2 overexpression enhances uptake of LDL, CLU, and APOE; Trem2 knockout microglia show reduced internalization. Aβ-lipoprotein complexes are taken up by microglia in a TREM2-dependent manner, and uptake is reduced in macrophages from human TREM2-AD-variant carriers.","method":"Protein microarray screen, Co-IP/binding assays, overexpression and knockout cell assays, human macrophage uptake assay","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased screen followed by multiple orthogonal validation methods (pulldown, KO, human cells); replicated concept across multiple groups","pmids":["27477018"],"is_preprint":false},{"year":2018,"finding":"TREM2 directly binds Aβ oligomers with nanomolar affinity; AD-associated TREM2 mutations reduce Aβ binding. TREM2 deficiency impairs Aβ degradation in primary microglia and mouse brain. Aβ-induced microglial responses (depolarization, K+ inward current, cytokine expression/secretion, migration, proliferation, apoptosis, morphological changes) are dependent on TREM2. Aβ enhances TREM2 interaction with its signaling adaptor DAP12, regulating downstream phosphorylation of SYK and GSK3β.","method":"Direct binding assay (nanomolar affinity measurement), primary microglial culture KO, mouse brain KO, Co-IP (TREM2–DAP12), phosphorylation assays (SYK, GSK3β), electrophysiology","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding assay, Co-IP, multiple functional readouts in primary cells and in vivo; rigorous single-study with multiple orthogonal methods","pmids":["29518356"],"is_preprint":false},{"year":2014,"finding":"TREM2 undergoes ectodomain shedding by ADAM proteases (α-secretases). FTD/FTD-like syndrome-associated missense mutations reduce TREM2 maturation, abolish ADAM-mediated shedding, and impair phagocytic activity of TREM2-expressing cells. Reduced shedding results in virtual absence of soluble TREM2 in CSF and plasma.","method":"Cell-based maturation and shedding assays, phagocytosis assays, CSF/plasma protein measurement in patients, protease inhibitor experiments","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (shedding assay, phagocytosis, patient biofluid), mechanistically defined sheddase as ADAM protease","pmids":["24990881"],"is_preprint":false},{"year":2017,"finding":"TREM2 sustains microglial metabolic fitness by enabling mTOR signaling. TREM2-deficient microglia in AD mice and in AD patients carrying TREM2 risk variants display abundant autophagic vesicles linked to defective mTOR signaling, reduced ATP levels, and impaired biosynthetic pathways. Metabolic rescue via cyclocreatine (ATP analog) restores microglial clustering around plaques and decreases neuronal dystrophy in TREM2-deficient AD mice.","method":"Combined metabolomics and RNA-seq, mouse models (TREM2-deficient with amyloid pathology), in vitro rescue experiments, dietary cyclocreatine intervention, autophagic vesicle quantification","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — metabolomics + RNA-seq + in vivo rescue + human patient tissue, multiple orthogonal methods in one rigorous study","pmids":["28802038"],"is_preprint":false},{"year":2017,"finding":"TREM2 induces APOE signaling, mediating a switch from a homeostatic to a neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons. Targeting the TREM2-APOE pathway restored homeostatic microglial signature in ALS and AD mouse models and prevented neuronal loss in an acute neurodegeneration model.","method":"Mouse models of ALS, MS, AD (genetic and pharmacological targeting), transcriptional profiling, apoptotic neuron phagocytosis assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — pathway epistasis in multiple disease models, transcriptional and functional rescue, replicated across disease contexts","pmids":["28930663"],"is_preprint":false},{"year":2019,"finding":"CD33 acts upstream of TREM2 in modulating microglial pathology in Alzheimer's disease. CD33 knockout attenuates Aβ pathology and improves cognition in 5xFAD mice, effects abrogated by additional TREM2 knockout. TREM2 knockout exacerbates Aβ pathology, and this cannot be rescued by CD33 knockout. RNA-seq shows phagocytosis- and signaling-related genes upregulated in 5xFAD;CD33-/- microglia depend on TREM2 presence.","method":"Genetic epistasis (double knockout mouse models), RNA-seq of sorted microglia, behavioral testing, amyloid burden quantification","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis with double KO, RNA-seq, multiple phenotypic readouts","pmids":["31301936"],"is_preprint":false},{"year":2019,"finding":"In the absence of functional TREM2, amyloid plaque seeding is increased due to reduced microglial clustering around newly seeded plaques and reduced plaque-associated ApoE deposition. Microglia are identified as one source of plaque-associated ApoE by microglia depletion experiments. Longitudinal amyloid PET demonstrates accelerated early amyloidogenesis in Trem2 loss-of-function mutants.","method":"Mouse models, microglia depletion experiments, proteomics, longitudinal amyloid small-animal PET, human brain tissue from TREM2 variant carriers","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (PET, proteomics, microglia depletion, human tissue validation)","pmids":["30617257"],"is_preprint":false},{"year":2020,"finding":"TREM2 is a key transcriptional regulator of cholesterol transport and metabolism under chronic phagocytic challenge. TREM2-deficient microglia phagocytose myelin debris but fail to clear myelin cholesterol, resulting in cholesteryl ester (CE) accumulation. CE accumulation is also observed in APOE-deficient glial cells. This is replicated in myelin-treated TREM2-deficient murine macrophages and human iPSC-derived microglia and rescued by ACAT1 inhibitor and LXR agonist.","method":"Chronic demyelination mouse model, cell sorting with RNA-seq and lipidomics, TREM2-deficient murine macrophages, human iPSC-derived microglia, pharmacological rescue (ACAT1 inhibitor, LXR agonist)","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — RNA-seq, lipidomics, human iPSC microglia, pharmacological rescue, replicated across multiple model systems","pmids":["31902528"],"is_preprint":false},{"year":2021,"finding":"TREM2 interacts with TDP-43 protein, as demonstrated by mass spectrometry and surface plasmon resonance in vitro and in vivo, and in human ALS tissues. TREM2 deficiency impairs phagocytic clearance of pathological TDP-43 by microglia and enhances neuronal damage. Computationally identified regions within hTDP-43 interact with TREM2.","method":"Mass spectrometry, surface plasmon resonance (SPR), mouse viral/transgenic models, mass cytometry, human ALS tissue","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding measured by SPR, MS identification, in vivo validation, human tissue confirmation","pmids":["34916658"],"is_preprint":false},{"year":2021,"finding":"TREM2-dependent lipid droplet biogenesis is required for remyelination. Cholesterol esterification in microglia/macrophages is a necessary adaptive response to myelin debris uptake. TREM2-deficient mice cannot adapt to excess cholesterol, form fewer lipid droplets, and accumulate ER stress. Alleviating ER stress in TREM2-deficient mice restores lipid droplet biogenesis and resolves the innate immune response, enabling remyelination.","method":"Demyelinating injury mouse model, TREM2 KO mice, ER stress assays, lipid droplet quantification, pharmacological ER stress relief","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse model with mechanistic rescue (ER stress relief restores lipid droplets), multiple orthogonal readouts","pmids":["34424266"],"is_preprint":false},{"year":2019,"finding":"Trem2 is a lipid-sensing receptor that controls lipid-associated macrophage (LAM) function in adipose tissue. Genetic ablation of Trem2 globally inhibits the downstream LAM transcriptional program, leading to adipocyte hypertrophy and systemic hypercholesterolemia, body fat accumulation, and glucose intolerance.","method":"Single-cell RNA sequencing (mouse and human), Trem2 genetic ablation, metabolic phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation with defined metabolic phenotypes, scRNA-seq in mouse and human, conserved across species","pmids":["31257031"],"is_preprint":false},{"year":2020,"finding":"TREM2-expressing regulatory myeloid (Mreg) cells with high Arginase 1 activity accumulate intratumorally. Genetic ablation of Trem2 inhibits accumulation of these Mreg cells, leading to decreased dysfunctional CD8+ T cells and reduced tumor growth.","method":"INs-seq (integrated scRNA-seq + intracellular protein activity profiling), Trem2 genetic ablation in mouse tumor models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — novel integrated technology with genetic ablation and defined immunological phenotypes","pmids":["32783915"],"is_preprint":false},{"year":2020,"finding":"The TREM2 transmembrane domain signals through the adaptor protein DAP12, which contains an ITAM motif. TREM2 ligation leads to Src family kinase activation, ITAM tyrosine phosphorylation, and recruitment of Syk and ZAP70 tyrosine kinases to initiate intracellular signaling cascade.","method":"Biochemical signaling assays, phosphorylation assays (referenced across multiple studies and review synthesis)","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — established across multiple labs but this paper is a review synthesis; original signaling mechanism replicated broadly","pmids":["23459077"],"is_preprint":false},{"year":2023,"finding":"TREM2 mediates phagocytosis via Syk signaling in glioma-associated myeloid cells. TREM2+ myeloid cells display enhanced tumor uptake compared to TREM2- cells. TREM2 expression is positively associated with phagocytosis markers LYZ and CD163.","method":"In vivo phagocytosis tracking assay, in vitro phagocytosis assays, scRNA-seq of human gliomas, Syk inhibitor experiments, mouse glioma models","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic Syk link demonstrated in vitro with inhibitor, in vivo tracking assay, human scRNA-seq correlation","pmids":["38237157"],"is_preprint":false},{"year":2021,"finding":"TREM2 recognizes non-glycosylated mycolic acid (MA)-containing lipids from Mycobacterium cell walls via TREM2/DAP12-dependent but CARD9-independent signaling. This recruits iNOS-negative mycobacterium-permissive macrophages, opposing Mincle-FcRγ-CARD9-driven anti-mycobacterial immunity. TREM2 deletion enhances Mincle-induced macrophage activation and accelerates mycobacterial elimination, indicating TREM2-DAP12 counteracts anti-mycobacterial immunity.","method":"Macrophage activation assays, genetic KO (TREM2 and DAP12 KO mice), in vivo infection model, pathway epistasis (Mincle vs TREM2/DAP12)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis, KO mice, in vitro and in vivo infection models, multiple orthogonal readouts","pmids":["33863908"],"is_preprint":false},{"year":2020,"finding":"TMEM59 (type I transmembrane protein) interacts with TREM2 (Co-IP). TREM2 overexpression promotes TMEM59 protein degradation, while Trem2-deficient microglia have elevated TMEM59 levels. Silencing TMEM59 rescues impaired survival, proliferation, migration, phagocytosis, and dysregulated autophagy and metabolism in Trem2-deficient microglia.","method":"Co-immunoprecipitation, overexpression and knockdown assays, Trem2-deficient microglia rescue experiments, autophagic flux assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP interaction plus functional rescue in Trem2-KO microglia, single lab","pmids":["32826884"],"is_preprint":false},{"year":2018,"finding":"LILRB2, an inhibitory receptor bearing ITIM motifs, co-ligates with TREM2 on shared ligands (oligomeric Aβ and phosphatidylserine), leading to significant inhibition of TREM2 signaling. An antagonistic LILRB2 antibody (Ab29) prevents this inhibition, enhancing TREM2 signaling, microglial phagocytosis, migration, and cytokine responses in human iPSC-derived microglia and in vivo in 5XFAD mice.","method":"Human iPSC-derived microglia functional assays, antagonistic antibody blocking, in vivo 5XFAD stereotaxic grafting, phospho-signaling assays","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human iPSC microglia, in vivo assay, antibody functional rescue; single lab","pmids":["35717259"],"is_preprint":false},{"year":2020,"finding":"Monoclonal antibody 4D9, targeting the stalk region epitope close to the TREM2 α-secretase cleavage site, reduces TREM2 shedding by ADAM10/17, stabilizes full-length TREM2 on the cell surface, and concomitantly activates phospho-SYK signaling. In vivo, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced the homeostatic marker in an AD mouse model.","method":"Antibody panel screening, shedding assays, phospho-SYK signaling assay, macrophage survival assay, myelin debris/Aβ phagocytosis in vitro, AD mouse model in vivo, CSF target engagement","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (shedding, signaling, phagocytosis, in vivo AD model, CSF biomarker), rigorous single study","pmids":["32154671"],"is_preprint":false},{"year":2022,"finding":"Trem2 deletion in microglia enhances tau trafficking to endosomal/pre-exosomal compartments after internalization (without affecting uptake), increases tau content in microglial exosomes, and elevates tau-seeding capacity of secreted exosomes. In vivo, Trem2 KO enhances tau spreading from medial entorhinal cortex to hippocampus, impairing synaptic function and memory.","method":"AAV-P301L tau injection model (MEC), microfluidic tau dispersion assay, exosome isolation and tau FRET reporter seeding assay, proteomics, exosome inhibitor experiments, mouse KO","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, mechanistic exosome pathway established","pmids":["36056435"],"is_preprint":false},{"year":2023,"finding":"Trem2 expression in microglia is required for maintaining normal neuronal bioenergetic profiles during postnatal development. In the absence of Trem2, CA1 (but not CA3) hippocampal pyramidal neurons display compromised energy metabolism, reduced mitochondrial mass, and abnormal organelle ultrastructure, accompanied by delayed neuronal maturation.","method":"Trem2 KO mouse model, single-cell/single-nucleus RNA sequencing, electron microscopy (mitochondrial ultrastructure), metabolic profiling of neurons by region","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with region-specific ultrastructural and transcriptional readouts, multiple orthogonal methods","pmids":["38159572"],"is_preprint":false},{"year":2023,"finding":"TREM2 is required for efficient efferocytosis in macrophages. TREM2 deficiency reduces the ability of foamy macrophages to take up oxidized LDL. Mechanistically, TREM2-deficient macrophages fail to upregulate cholesterol efflux molecules, resulting in impaired proliferation and survival. A genome-wide CRISPR screen identified Trem2 as associated with foamy macrophage specification.","method":"Genome-wide CRISPR screen, single-cell RNA sequencing trajectory analysis, myeloid-specific Trem2 KO mouse, oxLDL uptake assay, cholesterol efflux assay, atherosclerosis mouse model","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR screen, myeloid-specific KO, functional lipid uptake/efflux assays, in vivo atherosclerosis model","pmids":["38646596"],"is_preprint":false},{"year":2023,"finding":"TREM2 promotes macrophage efferocytosis and survival of lipid-laden macrophages in atherosclerosis. TREM2 deficiency increased necrotic core formation. TREM2 agonism decreased necrotic core formation. TREM2 is essential for the efferocytosis capacities of macrophages.","method":"Hematopoietic/global TREM2 KO mouse models, TREM2 agonist treatment, atherosclerosis mouse models, efferocytosis assays","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and pharmacological agonism, in vivo atherosclerosis model, efferocytosis assay","pmids":["38974464"],"is_preprint":false},{"year":2023,"finding":"TREM2 promotes cholesterol uptake and foam cell formation by upregulating scavenger receptor CD36 expression. Mechanistically, TREM2 inhibits phosphorylation of p38 MAPK and PPARγ, thereby increasing PPARγ nuclear transcriptional activity and promoting CD36 transcription. Trem2-/-/ApoE-/- mice show reduced atherosclerotic lesion size and lipid burden.","method":"ApoE-/- and Trem2-/-/ApoE-/- double-KO mouse models, TREM2 overexpression in SMCs and macrophages, oxLDL uptake assays, p38/PPARγ phosphorylation assays, CD36 transcription assay","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway (p38-PPARγ-CD36) defined in cell culture, confirmed with double-KO in vivo; single lab","pmids":["37133566"],"is_preprint":false},{"year":2024,"finding":"TREM2-expressing macrophages in cardiac ischemia (TREM2hi Mac1 subset) actively scavenge cardiomyocyte-ejected dysfunctional mitochondria. Trem2 deficiency impairs Mac1 self-renewal, leading to defective elimination of damaged mitochondria, excessive cardiac inflammation, exacerbated dysfunction, and decreased survival.","method":"scRNA-seq, fate mapping, Trem2 KO mouse model of sepsis, macrophage transfer experiments, mitochondria scavenging assays","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — fate mapping + scRNA-seq + Trem2 KO + adoptive transfer, multiple orthogonal methods","pmids":["36635449"],"is_preprint":false},{"year":2024,"finding":"In macrophages following efferocytosis, TREM2 decreases SLC25A53 transcription through the SYK-SMAD4 signaling pathway, impairing NAD+ transport into mitochondria and causing a breakpoint in the TCA cycle with increased itaconate production. Itaconate secreted by TREM2+ macrophages inhibits cardiomyocyte apoptosis and promotes fibroblast proliferation during MI repair.","method":"RNA-seq, protein interaction/molecular docking, targeted metabolomics (LC-MS), in vitro efferocytosis assays, macrophage-specific Trem2 KO mouse model of MI","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolomics + RNA-seq + molecular docking; signaling pathway (SYK-SMAD4-SLC25A53) not fully validated by orthogonal methods in single paper","pmids":["38182899"],"is_preprint":false},{"year":2023,"finding":"TREM2+ macrophages suppress NK cell accumulation and cytolytic activity in lung cancer by modulating IL-18/IL-18BP decoy interactions and IL-15 production. Genetic deletion of Trem2 rescues NK cell accumulation and enables NK cell-mediated tumor regression.","method":"Murine lung adenocarcinoma model, Trem2 genetic deletion, cytokine profiling (IL-18, IL-18BP, IL-15), NK cell functional assays, TREM2 blockade synergy with NK cell-activating agent","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cytokine mechanism, multiple functional assays, pharmacological synergy, human tumor correlation","pmids":["37081148"],"is_preprint":false},{"year":2023,"finding":"TREM2+ TAMs in hepatocellular carcinoma secrete less CXCL9 but more galectin-1 compared to TREM2- TAMs. Galectin-1 promotes PD-L1 overexpression in vessel endothelial cells, impeding CD8+ T cell recruitment. TREM2 deficiency increases CD8+ T cell infiltration and enhances anti-PD-L1 blockade efficacy.","method":"scRNA-seq, in vitro co-culture, TREM2-KO mouse models (orthotopic and spontaneous HCC), immunofluorescence, flow cytometry","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway (TREM2→galectin-1→PD-L1→CD8+ T cell exclusion) validated in vitro and in two in vivo models","pmids":["36889359"],"is_preprint":false},{"year":2023,"finding":"Soluble TREM2 (sTREM2) species (from both proteolytic shedding and alternatively spliced isoforms lacking transmembrane domain) inhibit long-term potentiation (LTP) in hippocampal brain slices, and this effect is abolished by the GABAA receptor antagonist picrotoxin.","method":"In vitro cleavage/secretion assays (HEK293T, HMC3), hippocampal LTP induction in brain slices, GABAA antagonist pharmacology, qPCR in AD patient post-mortem samples","journal":"Genome medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional LTP assay with pharmacological rescue, in vitro secretion validation; single lab","pmids":["36805764"],"is_preprint":false},{"year":2023,"finding":"TREM2 is important for virus-induced IFNB induction through the cGAS-STING DNA-sensing pathway in microglia and for phagocytosis of HSV1-infected neurons. TREM2 augments STING signaling and activation of downstream targets TBK1 and IRF3. TREM2 depletion increased susceptibility to HSV1 infection in human microglia-neuron co-cultures and mouse brain.","method":"hiPSC-derived microglia with TREM2 depletion, IFNB induction assays, cGAS-STING/TBK1/IRF3 signaling assays, phagocytosis assay, mouse in vivo HSV1 infection","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human iPSC microglia + in vivo mouse, cGAS-STING pathway validation, single lab","pmids":["37595041"],"is_preprint":false},{"year":2018,"finding":"TREM2 acts as a natural brake on TLR4-mediated proinflammatory signaling in hepatic macrophages and hepatic stellate cells. Trem2-deficient primary hepatic macrophages and stellate cells exhibit augmented TLR4-driven proinflammatory responses. Bone marrow transplantation experiments showed that both immune and resident cell TREM2 expression are required for full protection.","method":"Acute and chronic liver injury mouse models (Trem2 KO), primary hepatic macrophage isolation and TLR4 stimulation assays, bone marrow transplantation, ROS assays","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cell mechanistic assays + BM transplantation + in vivo KO; single lab","pmids":["29374630"],"is_preprint":false},{"year":2023,"finding":"TREM2 deficiency impairs glycolytic flux and oxidative metabolism in Schwann cells, triggering mitochondrial damage and autophagy via AMPK activation and impaired PI3K-AKT-mTOR signaling. This energy crisis in TREM2-deficient Schwann cells impairs cell proliferation and axonal regeneration, exacerbating neurological deficits in a mouse model of acute motor axonal neuropathy.","method":"TREM2 KO Schwann cell energy metabolism assays (glycolysis, oxidative phosphorylation), metabolomics, AMPK/PI3K-AKT-mTOR pathway analysis, sciatic nerve model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolomics + pathway analysis + in vivo mouse model; single lab, multiple methods","pmids":["38453910"],"is_preprint":false},{"year":2024,"finding":"TREM2 functions as a key braking mechanism for the NLRP3/NF-κB/IL-1β inflammasome pathway in pancreatic macrophages, opposing microbial LPS as an activator of this pathway. TREM2 depletion orchestrates with LPS to trigger IL-1β upregulation and pathogenic inflammation, fueling PDAC development. IL-1β inhibition or microbiome ablation reverses the accelerated PDAC progression caused by TREM2 depletion.","method":"KPPC;Trem2-/- transgenic mouse model, scRNA-seq, IL-1β inhibition experiments, antibiotic-mediated microbiome ablation, pathway analysis (NLRP3/NF-κB/IL-1β)","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in spontaneous tumor model, scRNA-seq, pharmacological rescue; single lab","pmids":["39956331"],"is_preprint":false},{"year":2024,"finding":"Microglia gravitate toward amyloid plaques surrounded by externalized phosphatidylserine (ePtdSer) from dystrophic neurons via TREM2. TREM2-mediated phagocytosis of Aβ is accelerated by ePtdSer. TREM2 loss-of-function (frameshift in exon 2) reduces phagocytic activity toward ePtdSer-positive Aβ plaques.","method":"2D/3D/4D co-culture systems with CRISPR-engineered TREM2 loss-of-function brain organoids/microglia/assembloids, APPNL-G-F/MAPT double knock-in mice, APOE4 iPSC lines","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR engineered organoid/assembloid system plus knock-in mouse model; single lab","pmids":["38981007"],"is_preprint":false},{"year":2023,"finding":"TREM2-IGF1 signaling axis regulates microglial functional and metabolic profiles, exerting neuroprotective effects in ischemic stroke. IGF1 is a major downstream molecule of Trem2. Overexpression of Igf1 and supplementation of cyclocreatine restore microglial glucometabolic levels and cellular functions even in the absence of Trem2.","method":"Single-nuclei RNA sequencing, microglial depletion (PLX3397) + repopulation, Trem2/Igf1 overexpression, cyclocreatine metabolic rescue, ischemic stroke mouse model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — snRNA-seq, pharmacological rescue, genetic manipulation; single lab with multiple methods","pmids":["38151703"],"is_preprint":false},{"year":2023,"finding":"Trem2 H157Y knock-in mutation increases TREM2 shedding, elevating soluble TREM2 levels in brain and serum. This enhances synaptic plasticity and, in the presence of amyloid pathology, accelerates Aβ clearance and reduces amyloid burden and dystrophic neurites. Targeted mass spectrometry shows higher ratios of soluble to full-length TREM2-H157Y versus WT TREM2.","method":"CRISPR/Cas9 knock-in mouse model, targeted mass spectrometry, biochemical assays, hippocampal electrophysiology (LTP), in vivo microdialysis, immunofluorescence, cortical bulk RNA-seq","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — knock-in mouse, targeted MS (shedding quantification), electrophysiology, in vivo microdialysis, multiple orthogonal methods in single rigorous study","pmids":["36721205"],"is_preprint":false}],"current_model":"TREM2 is a myeloid/microglial surface receptor that (1) senses lipids, lipoproteins (APOE, CLU), phosphatidylserine on damaged cells, Aβ oligomers, and TDP-43 via its extracellular immunoglobulin domain; (2) signals through the adaptor DAP12 via ITAM phosphorylation to activate Syk/ZAP70 and downstream mTOR, promoting microglial/macrophage survival, proliferation, migration, metabolic fitness (via mTOR), cholesterol handling, and phagocytic clearance; (3) is shed by ADAM10/17 α-secretases to produce a soluble form (sTREM2) that can inhibit LTP and modulate inflammation; (4) acts as a brake on TLR4 and NLRP3/NF-κB/IL-1β inflammatory signaling; (5) regulates lipid droplet biogenesis and cholesterol efflux under lipid-loading conditions; (6) drives APOE signaling to switch microglia from homeostatic to disease-associated states; and (7) disease-associated mutations (e.g., R47H) impair ligand sensing, receptor maturation, shedding, and downstream phagocytic function, increasing risk for Alzheimer's disease and other neurodegenerative conditions."},"narrative":{"mechanistic_narrative":"TREM2 is a myeloid and microglial transmembrane immunoreceptor that couples sensing of lipids, lipoproteins, and damage-associated ligands to phagocytic, metabolic, and immune-regulatory programs [PMID:25728668, PMID:27477018]. Its extracellular immunoglobulin domain directly binds anionic and zwitterionic lipids exposed on damaged neuronal membranes [PMID:25728668], apolipoproteins and lipoprotein particles including APOE, CLU/APOJ, and LDL [PMID:27477018], oligomeric Aβ with nanomolar affinity [PMID:29518356], externalized phosphatidylserine on dystrophic neurons [PMID:38981007], and pathological TDP-43 [PMID:34916658]; disease-associated mutations such as R47H reduce these binding events [PMID:25728668, PMID:27477018, PMID:29518356]. Ligand engagement signals through the ITAM-bearing adaptor DAP12, driving Src-family-kinase phosphorylation and recruitment of Syk/ZAP70 [PMID:23459077], a cascade enhanced by Aβ that controls downstream SYK and GSK3β phosphorylation [PMID:29518356] and ultimately sustains microglial survival, clustering, and phagocytosis [PMID:25728668, PMID:38237157]. Downstream of this axis, TREM2 supports cellular metabolic fitness by enabling mTOR signaling and ATP production, with metabolic rescue restoring microglial plaque clustering [PMID:28802038], and acts through an IGF1 axis to maintain microglial glucometabolism [PMID:38151703]. TREM2 governs cholesterol handling under phagocytic load: it is required to clear myelin-derived cholesterol and prevent cholesteryl ester accumulation [PMID:31902528] and to drive adaptive lipid droplet biogenesis that relieves ER stress and enables remyelination [PMID:34424266], and it controls lipid-associated macrophage programs in adipose, atherosclerotic, and tumor tissues [PMID:31257031, PMID:38646596, PMID:38974464]. It restrains inflammation, acting as a brake on TLR4 signaling [PMID:29374630] and the NLRP3/NF-κB/IL-1β inflammasome [PMID:39956331]. TREM2 is processed by ADAM α-secretases to release soluble TREM2; mutations that abolish shedding impair maturation and phagocytosis [PMID:24990881], and soluble TREM2 inhibits hippocampal long-term potentiation through a GABAA-dependent mechanism [PMID:36805764]. Through induction of APOE signaling, TREM2 drives the switch of microglia from a homeostatic to a disease-associated state during clearance of apoptotic neurons [PMID:28930663]. In Alzheimer's pathology, loss of functional TREM2 reduces microglial clustering and plaque-associated ApoE, accelerating amyloid seeding [PMID:30617257], and antibody stabilization of surface TREM2 or activating mutations that increase shedding can reduce amyloidogenesis [PMID:32154671, PMID:36721205]. Across cancers, TREM2-expressing regulatory and tumor-associated myeloid cells suppress CD8+ T-cell and NK-cell antitumor immunity [PMID:32783915, PMID:37081148, PMID:36889359].","teleology":[{"year":2014,"claim":"Established that TREM2 is post-translationally processed and that pathogenic mutations act by impairing maturation and shedding, linking receptor biogenesis to phagocytic function and biofluid sTREM2 levels.","evidence":"Cell-based maturation/shedding and phagocytosis assays with patient CSF/plasma measurement","pmids":["24990881"],"confidence":"High","gaps":["Did not define which ADAM protease predominates in vivo","Functional role of the released soluble ectodomain not established"]},{"year":2015,"claim":"Identified TREM2 as a direct lipid sensor for damaged-membrane and Aβ-associated lipids whose engagement triggers tyrosine phosphorylation and is required for microglial survival and plaque clustering, providing the first ligand-driven mechanism for AD risk.","evidence":"Lipid-binding assays plus 5XFAD knockout/haploinsufficient mouse microglial clustering and survival readouts","pmids":["25728668"],"confidence":"High","gaps":["Did not resolve the precise lipid headgroup specificity","How lipid binding is mechanically transduced to DAP12 not defined"]},{"year":2016,"claim":"Showed TREM2 binds apolipoproteins and lipoprotein particles and mediates their uptake, connecting receptor ligand recognition to lipid/lipoprotein clearance and explaining APOE/CLU-related risk convergence.","evidence":"Unbiased protein microarray screen with pulldown, overexpression/KO uptake assays, and human variant-carrier macrophages","pmids":["27477018"],"confidence":"High","gaps":["Binding affinities and lipidation-state dependence not fully quantified","Intracellular routing of internalized lipoproteins not traced"]},{"year":2017,"claim":"Linked TREM2 signaling to microglial bioenergetics by showing it sustains mTOR-dependent metabolic fitness, and demonstrated that metabolic supplementation restores plaque clustering, reframing TREM2 dysfunction as a metabolic deficit.","evidence":"Metabolomics + RNA-seq, TREM2-deficient amyloid mice, human variant tissue, and dietary cyclocreatine rescue","pmids":["28802038"],"confidence":"High","gaps":["The signaling steps from DAP12/Syk to mTOR not delineated","Whether metabolic rescue translates to humans untested"]},{"year":2017,"claim":"Defined a TREM2-APOE axis that switches microglia from homeostatic to neurodegenerative states after engulfing apoptotic neurons, establishing TREM2 as a master regulator of disease-associated microglial identity.","evidence":"Transcriptional profiling and genetic/pharmacological targeting across ALS, MS, and AD mouse models","pmids":["28930663"],"confidence":"High","gaps":["Direction of causality between TREM2 and APOE induction not fully resolved","Transcription factors executing the state switch not identified"]},{"year":2018,"claim":"Demonstrated direct nanomolar Aβ-oligomer binding and that Aβ enhances TREM2-DAP12 coupling and SYK/GSK3β phosphorylation, showing Aβ itself is an activating ligand controlling microglial responses and degradation.","evidence":"Direct binding assays, Co-IP, phosphorylation and electrophysiology in primary microglia and mouse brain KO","pmids":["29518356"],"confidence":"High","gaps":["Whether monomeric vs oligomeric Aβ differ mechanistically not fully dissected","Relationship between Aβ binding and lipid/lipoprotein binding sites unresolved"]},{"year":2018,"claim":"Established TREM2 as a brake on TLR4-driven proinflammatory signaling in liver, extending its function beyond brain to a general anti-inflammatory rheostat in tissue macrophages.","evidence":"Trem2 KO liver injury models, primary hepatic macrophage TLR4 stimulation, and bone marrow transplantation","pmids":["29374630"],"confidence":"Medium","gaps":["Molecular mechanism by which TREM2 antagonizes TLR4 not defined","Single lab; reciprocal signaling crosstalk not mapped"]},{"year":2019,"claim":"Placed TREM2 within a CD33-TREM2 epistatic hierarchy in AD, showing CD33's protective effects require functional TREM2 and that TREM2 loss cannot be compensated, defining pathway order among AD myeloid risk genes.","evidence":"Double-knockout mouse genetic epistasis with RNA-seq, behavior, and amyloid quantification","pmids":["31301936"],"confidence":"High","gaps":["Biochemical link between CD33 and TREM2 signaling not established","Whether interaction is direct or convergent unresolved"]},{"year":2019,"claim":"Showed that loss of TREM2 function accelerates early amyloid seeding via reduced microglial clustering and plaque-associated ApoE deposition, identifying microglia as an ApoE source shaping plaque formation.","evidence":"Longitudinal amyloid PET, proteomics, microglia depletion, and human variant-carrier tissue","pmids":["30617257"],"confidence":"High","gaps":["Mechanism by which microglial ApoE limits seeding not fully defined","Temporal window of intervention unclear"]},{"year":2019,"claim":"Generalized TREM2 as the controller of a lipid-associated macrophage program governing systemic metabolism, linking its loss to adipocyte hypertrophy, hypercholesterolemia, and glucose intolerance.","evidence":"Single-cell RNA-seq in mouse and human with Trem2 ablation and metabolic phenotyping","pmids":["31257031"],"confidence":"High","gaps":["Ligand triggering the LAM program in adipose not identified","Causal step from TREM2 signaling to transcriptional LAM program unmapped"]},{"year":2020,"claim":"Defined TREM2 as a transcriptional regulator of cholesterol transport under chronic phagocytic challenge, with loss causing cholesteryl ester accumulation rescuable by ACAT1 inhibition or LXR agonism.","evidence":"Chronic demyelination model, RNA-seq/lipidomics, murine and human iPSC microglia, pharmacological rescue","pmids":["31902528"],"confidence":"High","gaps":["Direct transcriptional targets controlling efflux not enumerated","Link from surface receptor to nuclear lipid programs incomplete"]},{"year":2020,"claim":"Consolidated the canonical TREM2 signaling module: transmembrane association with ITAM-bearing DAP12, Src-family kinase activation, and Syk/ZAP70 recruitment, providing the proximal signaling framework.","evidence":"Review synthesis of biochemical signaling and phosphorylation assays across labs","pmids":["23459077"],"confidence":"Medium","gaps":["Review synthesis rather than primary mechanism in one system","Quantitative stoichiometry of TREM2-DAP12 not addressed"]},{"year":2020,"claim":"Identified TMEM59 as a TREM2-interacting protein whose degradation depends on TREM2 and whose silencing rescues multiple Trem2-deficient phenotypes, nominating a downstream effector node.","evidence":"Co-IP, overexpression/knockdown, and rescue in Trem2-deficient microglia","pmids":["32826884"],"confidence":"Medium","gaps":["Single Co-IP without structural validation of the interaction","Mechanism of TREM2-driven TMEM59 degradation not defined"]},{"year":2020,"claim":"Demonstrated antibody stabilization of surface TREM2 by blocking shedding near the cleavage site activates phospho-SYK signaling and reduces amyloidogenesis, validating shedding control as a therapeutic lever.","evidence":"Antibody 4D9 shedding/signaling/phagocytosis assays plus AD mouse model with CSF target engagement","pmids":["32154671"],"confidence":"High","gaps":["Whether surface stabilization or epitope agonism dominates not separated","Long-term consequences of chronic TREM2 activation untested"]},{"year":2020,"claim":"Revealed an immunosuppressive role for TREM2+ regulatory myeloid cells in tumors, where Trem2 ablation reduces their accumulation and restores antitumor CD8+ T-cell function.","evidence":"Integrated scRNA-seq/protein-activity profiling (INs-seq) with Trem2 ablation in tumor models","pmids":["32783915"],"confidence":"High","gaps":["Ligand driving intratumoral Mreg differentiation unidentified","Whether effect requires DAP12 signaling not tested here"]},{"year":2021,"claim":"Showed TREM2 recognizes mycobacterial mycolic-acid lipids and that TREM2-DAP12 counteracts protective Mincle-CARD9 immunity, demonstrating context-dependent immunosuppression in infection.","evidence":"Macrophage activation assays, TREM2 and DAP12 KO mice, and pathway epistasis with Mincle","pmids":["33863908"],"confidence":"High","gaps":["Structural basis of mycolic acid recognition not resolved","How TREM2 and Mincle outputs are integrated in one cell unclear"]},{"year":2021,"claim":"Established TREM2-dependent lipid droplet biogenesis as an adaptive response that relieves ER stress and enables remyelination, mechanistically connecting lipid storage to inflammation resolution.","evidence":"Demyelinating injury KO mice with ER stress assays, lipid droplet quantification, and pharmacological ER stress relief","pmids":["34424266"],"confidence":"High","gaps":["Signaling link from TREM2 to droplet biogenesis machinery not defined","Relationship to the cholesterol efflux pathway not integrated"]},{"year":2021,"claim":"Identified TDP-43 as a TREM2 ligand and showed TREM2 is required for microglial clearance of pathological TDP-43, extending TREM2 ligand sensing to a major ALS/FTD aggregate.","evidence":"Mass spectrometry, SPR binding, mouse models, and human ALS tissue","pmids":["34916658"],"confidence":"High","gaps":["Binding interface mapped only computationally","Whether clearance proceeds via canonical DAP12 signaling untested"]},{"year":2022,"claim":"Showed TREM2 restrains tau propagation by limiting trafficking of internalized tau into exosomes, revealing a degradation-versus-spreading checkpoint distinct from uptake.","evidence":"AAV-tau model, exosome FRET seeding assays, proteomics, and Trem2 KO spreading studies","pmids":["36056435"],"confidence":"High","gaps":["Molecular machinery diverting tau to exosomes vs degradation unknown","Whether TREM2 acts on tau directly or via metabolic state unclear"]},{"year":2023,"claim":"Defined a TREM2-IGF1 axis maintaining microglial glucometabolism with neuroprotective effects in stroke, where IGF1 overexpression or cyclocreatine rescues Trem2-deficient deficits.","evidence":"snRNA-seq, microglial depletion/repopulation, genetic and metabolic rescue in ischemic stroke mice","pmids":["38151703"],"confidence":"Medium","gaps":["Direct transcriptional control of Igf1 by TREM2 signaling not proven","Single lab; human relevance untested"]},{"year":2023,"claim":"Showed TREM2 in microglia is required for normal neuronal bioenergetics during postnatal development, revealing a non-cell-autonomous role in neuronal maturation independent of disease.","evidence":"Trem2 KO mice with region-specific single-cell RNA-seq, electron microscopy, and neuronal metabolic profiling","pmids":["38159572"],"confidence":"High","gaps":["Microglia-to-neuron signal mediating bioenergetic support unidentified","Why CA1 but not CA3 neurons are affected unexplained"]},{"year":2023,"claim":"Demonstrated soluble TREM2 species inhibit hippocampal LTP through a GABAA-dependent mechanism, assigning a distinct gain-of-function activity to the shed/spliced ectodomain.","evidence":"In vitro secretion assays, hippocampal LTP recordings with picrotoxin, and AD post-mortem qPCR","pmids":["36805764"],"confidence":"Medium","gaps":["sTREM2 receptor/binding partner mediating GABAA effect unknown","Single lab; in vivo physiological relevance not established"]},{"year":2023,"claim":"Showed TREM2 augments antiviral cGAS-STING-TBK1-IRF3 signaling and phagocytosis of infected neurons, adding an antiviral arm to TREM2 myeloid function.","evidence":"hiPSC microglia with TREM2 depletion, IFNB and STING-pathway assays, and in vivo HSV1 infection","pmids":["37595041"],"confidence":"Medium","gaps":["How TREM2 connects to the cytosolic DNA-sensing pathway not defined","Single lab; specificity for DNA viruses untested"]},{"year":2023,"claim":"Showed an activating H157Y knock-in increases shedding and elevated soluble TREM2, enhancing synaptic plasticity and accelerating amyloid clearance, demonstrating that increased shedding can be beneficial in amyloid context.","evidence":"CRISPR knock-in mice, targeted MS shedding quantification, LTP, and in vivo microdialysis","pmids":["36721205"],"confidence":"High","gaps":["Reconciliation with sTREM2-mediated LTP inhibition not resolved","Whether benefit reflects full-length loss or soluble gain unclear"]},{"year":2023,"claim":"Established TREM2 as essential for macrophage efferocytosis and cholesterol efflux in atherosclerosis, with deficiency enlarging necrotic cores and agonism reducing them, broadening cardiovascular relevance.","evidence":"Genome-wide CRISPR screen, myeloid-specific and global KO, oxLDL uptake/efflux assays, and agonist treatment in atherosclerosis models","pmids":["38646596","38974464"],"confidence":"High","gaps":["Transcriptional effectors of efflux downstream of TREM2 not enumerated","Whether efferocytosis defect is metabolic or signaling-driven unresolved"]},{"year":2023,"claim":"Defined a TREM2-p38/PPARγ-CD36 pathway promoting cholesterol uptake and foam cell formation, providing a transcriptional mechanism for TREM2-driven lipid loading.","evidence":"ApoE-/- and Trem2-/-/ApoE-/- mice, overexpression, oxLDL uptake, and p38/PPARγ/CD36 assays","pmids":["37133566"],"confidence":"Medium","gaps":["Single lab; pathway not validated by orthogonal genetics","Apparent tension with protective efferocytosis role not reconciled"]},{"year":2023,"claim":"Showed TREM2+ tumor-associated macrophages suppress NK and CD8+ T-cell antitumor immunity via cytokine decoy and galectin-1/PD-L1 mechanisms, nominating TREM2 as an immunotherapy target across cancers.","evidence":"scRNA-seq, co-culture, Trem2 KO tumor models, cytokine profiling, and checkpoint-blockade synergy","pmids":["37081148","36889359"],"confidence":"High","gaps":["Whether immunosuppression requires TREM2 ligand sensing untested","Mechanism linking TREM2 to galectin-1/IL-18BP output not defined"]},{"year":2024,"claim":"Showed TREM2+ macrophages scavenge ejected dysfunctional mitochondria and that TREM2 supports their self-renewal, protecting against cardiac inflammation and dysfunction.","evidence":"scRNA-seq, fate mapping, Trem2 KO cardiac injury, and adoptive transfer with mitochondria scavenging assays","pmids":["36635449"],"confidence":"High","gaps":["Receptor-ligand basis of mitochondrial recognition not defined","Link to canonical DAP12/Syk signaling not tested"]},{"year":2024,"claim":"Linked post-efferocytosis TREM2-SYK-SMAD4 signaling to SLC25A53 repression, mitochondrial NAD+ limitation, and itaconate secretion that supports cardiac repair, connecting TREM2 to immunometabolite output.","evidence":"RNA-seq, targeted metabolomics, molecular docking, and macrophage-specific Trem2 KO MI model","pmids":["38182899"],"confidence":"Medium","gaps":["SYK-SMAD4-SLC25A53 axis not validated by orthogonal methods","Direct TREM2 control over SMAD4 not demonstrated"]},{"year":2024,"claim":"Established TREM2 as a brake on the NLRP3/NF-κB/IL-1β inflammasome opposing LPS, with loss accelerating pancreatic tumor progression reversible by IL-1β inhibition or microbiome ablation.","evidence":"KPPC;Trem2-/- mice, scRNA-seq, IL-1β inhibition, and antibiotic microbiome ablation","pmids":["39956331"],"confidence":"Medium","gaps":["Molecular mechanism of inflammasome restraint not defined","Single lab; whether brake is direct or metabolic unclear"]},{"year":2024,"claim":"Showed externalized phosphatidylserine on dystrophic neurons guides TREM2-mediated microglial recruitment and accelerates Aβ phagocytosis, with loss-of-function reducing clearance of ePtdSer-positive plaques.","evidence":"CRISPR loss-of-function organoids/assembloids, knock-in mice, and APOE4 iPSC lines in multidimensional co-cultures","pmids":["38981007"],"confidence":"Medium","gaps":["Single lab; direct PtdSer-TREM2 binding affinity not quantified here","How ePtdSer and Aβ co-signals are integrated unresolved"]},{"year":null,"claim":"How TREM2's diverse ligand inputs are integrated at the receptor to produce distinct context-specific transcriptional and metabolic outputs, and how soluble TREM2's beneficial versus inhibitory activities are reconciled, remain unresolved.","evidence":"No single discovery in the corpus unifies ligand integration with output specification or sTREM2 dual roles","pmids":[],"confidence":"Low","gaps":["No structural model linking specific ligands to specific signaling outputs","sTREM2 receptor and its physiological role undefined","Mechanism converting surface signaling into nuclear lipid/metabolic programs incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2,13]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1,8]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[1,21,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[30,32]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,13,18]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,28,35]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[19]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,15,30,32]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,8,11,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,13,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,5,7,26]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,2,14,21,22]}],"complexes":["TREM2-DAP12 receptor-adaptor complex"],"partners":["DAP12","APOE","CLU","TDP-43","TMEM59","LILRB2","SYK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NZC2","full_name":"Triggering receptor expressed on myeloid cells 2","aliases":["Triggering receptor expressed on monocytes 2"],"length_aa":230,"mass_kda":25.4,"function":"Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding (PubMed:10799849). Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia (PubMed:27477018, PubMed:29518356). Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, and the anti-inflammatory cytokine ARG1 (By similarity). Acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia (PubMed:27477018). Binds phospholipids (preferably anionic lipids) such as phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin (PubMed:29794134). Regulates microglial proliferation by acting as an upstream regulator of the Wnt/beta-catenin signaling cascade (By similarity). Required for microglial phagocytosis of apoptotic neurons (PubMed:24990881). Also required for microglial activation and phagocytosis of myelin debris after neuronal injury and of neuronal synapses during synapse elimination in the developing brain (By similarity). Regulates microglial chemotaxis and process outgrowth, and also the microglial response to oxidative stress and lipopolysaccharide (By similarity). It suppresses PI3K and NF-kappa-B signaling in response to lipopolysaccharide; thus promoting phagocytosis, suppressing pro-inflammatory cytokine and nitric oxide production, inhibiting apoptosis and increasing expression of IL10 and TGFB (By similarity). During oxidative stress, it promotes anti-apoptotic NF-kappa-B signaling and ERK signaling (By similarity). Plays a role in microglial MTOR activation and metabolism (By similarity). Regulates age-related changes in microglial numbers (PubMed:29752066). Triggers activation of the immune responses in macrophages and dendritic cells (PubMed:10799849). Mediates cytokine-induced formation of multinucleated giant cells which are formed by the fusion of macrophages (By similarity). In dendritic cells, receptor of SEMA6D with PLEXNA1 as coreceptor and mediates up-regulation of chemokine receptor CCR7 and dendritic cell maturation and survival (PubMed:11602640). Involved in the positive regulation of osteoclast differentiation (PubMed:12925681)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9NZC2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TREM2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TREM2","total_profiled":1310},"omim":[{"mim_id":"620845","title":"TRANSMEMBRANE 4 L6 FAMILY, MEMBER 19; TM4SF19","url":"https://www.omim.org/entry/620845"},{"mim_id":"618193","title":"POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY 2; PLOSL2","url":"https://www.omim.org/entry/618193"},{"mim_id":"615080","title":"ALZHEIMER DISEASE 17; AD17","url":"https://www.omim.org/entry/615080"},{"mim_id":"609716","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 3; TREML3","url":"https://www.omim.org/entry/609716"},{"mim_id":"609715","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 2; TREML2","url":"https://www.omim.org/entry/609715"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":58.6},{"tissue":"choroid plexus","ntpm":55.1}],"url":"https://www.proteinatlas.org/search/TREM2"},"hgnc":{"alias_symbol":["TREM-2","Trem2a","Trem2b","Trem2c"],"prev_symbol":[]},"alphafold":{"accession":"Q9NZC2","domains":[{"cath_id":"2.60.40.10","chopping":"17-132","consensus_level":"medium","plddt":95.1626,"start":17,"end":132}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZC2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZC2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZC2-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TREM2","jax_strain_url":"https://www.jax.org/strain/search?query=TREM2"},"sequence":{"accession":"Q9NZC2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NZC2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NZC2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZC2"}},"corpus_meta":[{"pmid":"23150934","id":"PMC_23150934","title":"TREM2 variants in Alzheimer's disease.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23150934","citation_count":2399,"is_preprint":false},{"pmid":"28930663","id":"PMC_28930663","title":"The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28930663","citation_count":2203,"is_preprint":false},{"pmid":"25728668","id":"PMC_25728668","title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25728668","citation_count":1416,"is_preprint":false},{"pmid":"31257031","id":"PMC_31257031","title":"Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31257031","citation_count":1067,"is_preprint":false},{"pmid":"28802038","id":"PMC_28802038","title":"TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28802038","citation_count":978,"is_preprint":false},{"pmid":"31932797","id":"PMC_31932797","title":"Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.","date":"2020","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31932797","citation_count":875,"is_preprint":false},{"pmid":"27477018","id":"PMC_27477018","title":"TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27477018","citation_count":730,"is_preprint":false},{"pmid":"24990881","id":"PMC_24990881","title":"TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24990881","citation_count":643,"is_preprint":false},{"pmid":"29518356","id":"PMC_29518356","title":"TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29518356","citation_count":576,"is_preprint":false},{"pmid":"30266932","id":"PMC_30266932","title":"TREM2 - a key player in microglial biology and Alzheimer disease.","date":"2018","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30266932","citation_count":573,"is_preprint":false},{"pmid":"31902528","id":"PMC_31902528","title":"TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/31902528","citation_count":569,"is_preprint":false},{"pmid":"32531244","id":"PMC_32531244","title":"The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32531244","citation_count":495,"is_preprint":false},{"pmid":"30140051","id":"PMC_30140051","title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.","date":"2018","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30140051","citation_count":465,"is_preprint":false},{"pmid":"30617257","id":"PMC_30617257","title":"Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.","date":"2019","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30617257","citation_count":430,"is_preprint":false},{"pmid":"32783915","id":"PMC_32783915","title":"Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32783915","citation_count":401,"is_preprint":false},{"pmid":"31590042","id":"PMC_31590042","title":"Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/ TLR4/ NF-κB pathways in BV2 cells.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31590042","citation_count":362,"is_preprint":false},{"pmid":"28768545","id":"PMC_28768545","title":"TREM2 in Neurodegenerative Diseases.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28768545","citation_count":351,"is_preprint":false},{"pmid":"28442216","id":"PMC_28442216","title":"TREM2, Microglia, and Neurodegenerative Diseases.","date":"2017","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28442216","citation_count":342,"is_preprint":false},{"pmid":"31301936","id":"PMC_31301936","title":"TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.","date":"2019","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/31301936","citation_count":297,"is_preprint":false},{"pmid":"34686340","id":"PMC_34686340","title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34686340","citation_count":286,"is_preprint":false},{"pmid":"32154671","id":"PMC_32154671","title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32154671","citation_count":246,"is_preprint":false},{"pmid":"28432014","id":"PMC_28432014","title":"TREM2-Ligand Interactions in Health and Disease.","date":"2017","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28432014","citation_count":220,"is_preprint":false},{"pmid":"29361745","id":"PMC_29361745","title":"Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29361745","citation_count":220,"is_preprint":false},{"pmid":"37081148","id":"PMC_37081148","title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37081148","citation_count":192,"is_preprint":false},{"pmid":"24355566","id":"PMC_24355566","title":"TREM2 and the neuroimmunology of Alzheimer's disease.","date":"2013","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24355566","citation_count":182,"is_preprint":false},{"pmid":"36889359","id":"PMC_36889359","title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36889359","citation_count":181,"is_preprint":false},{"pmid":"36635449","id":"PMC_36635449","title":"TREM2hi resident macrophages protect the septic heart by maintaining cardiomyocyte homeostasis.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36635449","citation_count":171,"is_preprint":false},{"pmid":"32840654","id":"PMC_32840654","title":"APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/32840654","citation_count":169,"is_preprint":false},{"pmid":"35750138","id":"PMC_35750138","title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35750138","citation_count":169,"is_preprint":false},{"pmid":"33516818","id":"PMC_33516818","title":"TREM2, microglia, and Alzheimer's disease.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/33516818","citation_count":168,"is_preprint":false},{"pmid":"35933399","id":"PMC_35933399","title":"Spatiotemporal dynamics of macrophage heterogeneity and a potential function of Trem2hi macrophages in infarcted hearts.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35933399","citation_count":158,"is_preprint":false},{"pmid":"30930146","id":"PMC_30930146","title":"A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30930146","citation_count":150,"is_preprint":false},{"pmid":"34424266","id":"PMC_34424266","title":"TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34424266","citation_count":144,"is_preprint":false},{"pmid":"26337043","id":"PMC_26337043","title":"TREM2 in CNS homeostasis and neurodegenerative disease.","date":"2015","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/26337043","citation_count":141,"is_preprint":false},{"pmid":"38646596","id":"PMC_38646596","title":"Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis.","date":"2023","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/38646596","citation_count":137,"is_preprint":false},{"pmid":"29374630","id":"PMC_29374630","title":"Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.","date":"2018","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/29374630","citation_count":133,"is_preprint":false},{"pmid":"36219197","id":"PMC_36219197","title":"Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36219197","citation_count":122,"is_preprint":false},{"pmid":"34916658","id":"PMC_34916658","title":"TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.","date":"2021","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34916658","citation_count":120,"is_preprint":false},{"pmid":"26854967","id":"PMC_26854967","title":"TREM2 Function in Alzheimer's Disease and Neurodegeneration.","date":"2016","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26854967","citation_count":112,"is_preprint":false},{"pmid":"36056435","id":"PMC_36056435","title":"Trem2 deletion enhances tau dispersion and pathology through microglia exosomes.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/36056435","citation_count":109,"is_preprint":false},{"pmid":"35867799","id":"PMC_35867799","title":"TREM2 macrophages induced by human lipids drive inflammation in acne lesions.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35867799","citation_count":107,"is_preprint":false},{"pmid":"35041990","id":"PMC_35041990","title":"Soluble TREM2: Innocent bystander or active player in neurological diseases?","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35041990","citation_count":102,"is_preprint":false},{"pmid":"32907830","id":"PMC_32907830","title":"TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.","date":"2020","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/32907830","citation_count":99,"is_preprint":false},{"pmid":"23407992","id":"PMC_23407992","title":"TREM2 in Alzheimer's disease.","date":"2013","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/23407992","citation_count":99,"is_preprint":false},{"pmid":"37172094","id":"PMC_37172094","title":"TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37172094","citation_count":98,"is_preprint":false},{"pmid":"37517293","id":"PMC_37517293","title":"TREM2: Potential therapeutic targeting of microglia for Alzheimer's disease.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37517293","citation_count":92,"is_preprint":false},{"pmid":"36368315","id":"PMC_36368315","title":"TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.","date":"2022","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/36368315","citation_count":90,"is_preprint":false},{"pmid":"38974464","id":"PMC_38974464","title":"TREM2 protects from atherosclerosis by limiting necrotic core formation.","date":"2024","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/38974464","citation_count":88,"is_preprint":false},{"pmid":"32635934","id":"PMC_32635934","title":"TREM2 ectodomain and its soluble form in Alzheimer's disease.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32635934","citation_count":86,"is_preprint":false},{"pmid":"38182899","id":"PMC_38182899","title":"TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38182899","citation_count":85,"is_preprint":false},{"pmid":"23459077","id":"PMC_23459077","title":"Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12.","date":"2013","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23459077","citation_count":85,"is_preprint":false},{"pmid":"39172787","id":"PMC_39172787","title":"Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39172787","citation_count":82,"is_preprint":false},{"pmid":"36107206","id":"PMC_36107206","title":"Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36107206","citation_count":80,"is_preprint":false},{"pmid":"27662313","id":"PMC_27662313","title":"Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model.","date":"2017","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27662313","citation_count":80,"is_preprint":false},{"pmid":"38617547","id":"PMC_38617547","title":"TREM2 promotes macrophage polarization from M1 to M2 and suppresses osteoarthritis through the NF-κB/CXCL3 axis.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38617547","citation_count":79,"is_preprint":false},{"pmid":"31068200","id":"PMC_31068200","title":"TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.","date":"2019","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/31068200","citation_count":78,"is_preprint":false},{"pmid":"38159572","id":"PMC_38159572","title":"Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38159572","citation_count":73,"is_preprint":false},{"pmid":"33863908","id":"PMC_33863908","title":"TREM2 is a receptor for non-glycosylated mycolic acids of mycobacteria that limits anti-mycobacterial macrophage activation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33863908","citation_count":71,"is_preprint":false},{"pmid":"37133566","id":"PMC_37133566","title":"TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37133566","citation_count":69,"is_preprint":false},{"pmid":"30038567","id":"PMC_30038567","title":"TREM2-Dependent Effects on Microglia in Alzheimer's Disease.","date":"2018","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30038567","citation_count":69,"is_preprint":false},{"pmid":"35750136","id":"PMC_35750136","title":"TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35750136","citation_count":67,"is_preprint":false},{"pmid":"36989543","id":"PMC_36989543","title":"TREM2: A new player in the tumor microenvironment.","date":"2023","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36989543","citation_count":63,"is_preprint":false},{"pmid":"29655369","id":"PMC_29655369","title":"TREM2 regulates innate immunity in Alzheimer's disease.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29655369","citation_count":63,"is_preprint":false},{"pmid":"33297569","id":"PMC_33297569","title":"Function of TREM1 and TREM2 in Liver-Related Diseases.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33297569","citation_count":60,"is_preprint":false},{"pmid":"38478630","id":"PMC_38478630","title":"Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38478630","citation_count":55,"is_preprint":false},{"pmid":"35746551","id":"PMC_35746551","title":"Exploring the Impact of TREM2 in Tumor-Associated Macrophages.","date":"2022","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/35746551","citation_count":52,"is_preprint":false},{"pmid":"38695172","id":"PMC_38695172","title":"Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report.","date":"2024","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38695172","citation_count":49,"is_preprint":false},{"pmid":"35717259","id":"PMC_35717259","title":"LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/35717259","citation_count":46,"is_preprint":false},{"pmid":"40247363","id":"PMC_40247363","title":"TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/40247363","citation_count":44,"is_preprint":false},{"pmid":"37003186","id":"PMC_37003186","title":"TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37003186","citation_count":44,"is_preprint":false},{"pmid":"34689040","id":"PMC_34689040","title":"Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2.","date":"2021","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34689040","citation_count":44,"is_preprint":false},{"pmid":"38769824","id":"PMC_38769824","title":"Microglia, Trem2, and Neurodegeneration.","date":"2024","source":"The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38769824","citation_count":42,"is_preprint":false},{"pmid":"38020891","id":"PMC_38020891","title":"The role of TREM2 in Alzheimer's disease: from the perspective of Tau.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38020891","citation_count":42,"is_preprint":false},{"pmid":"36119485","id":"PMC_36119485","title":"The therapeutic potential of TREM2 in cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36119485","citation_count":41,"is_preprint":false},{"pmid":"36625077","id":"PMC_36625077","title":"TREM2-dependent microglial function is essential for remyelination and subsequent neuroprotection.","date":"2023","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/36625077","citation_count":40,"is_preprint":false},{"pmid":"38151703","id":"PMC_38151703","title":"TREM2-IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38151703","citation_count":39,"is_preprint":false},{"pmid":"37740498","id":"PMC_37740498","title":"Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37740498","citation_count":39,"is_preprint":false},{"pmid":"37239970","id":"PMC_37239970","title":"TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer's Disease.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37239970","citation_count":35,"is_preprint":false},{"pmid":"38237157","id":"PMC_38237157","title":"Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.","date":"2024","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38237157","citation_count":34,"is_preprint":false},{"pmid":"37024448","id":"PMC_37024448","title":"TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37024448","citation_count":34,"is_preprint":false},{"pmid":"37595041","id":"PMC_37595041","title":"TREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37595041","citation_count":34,"is_preprint":false},{"pmid":"35003116","id":"PMC_35003116","title":"Targeting TREM2 for Parkinson's Disease: Where to Go?","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35003116","citation_count":34,"is_preprint":false},{"pmid":"34275100","id":"PMC_34275100","title":"Role of TREM2 in Alzheimer's Disease: A Long Road Ahead.","date":"2021","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34275100","citation_count":34,"is_preprint":false},{"pmid":"36805764","id":"PMC_36805764","title":"TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.","date":"2023","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36805764","citation_count":34,"is_preprint":false},{"pmid":"38821351","id":"PMC_38821351","title":"Microglia and TREM2.","date":"2024","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38821351","citation_count":33,"is_preprint":false},{"pmid":"38981007","id":"PMC_38981007","title":"Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38981007","citation_count":33,"is_preprint":false},{"pmid":"34874625","id":"PMC_34874625","title":"Microglial TREM2 in amyotrophic lateral sclerosis.","date":"2021","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34874625","citation_count":33,"is_preprint":false},{"pmid":"35153729","id":"PMC_35153729","title":"Does Soluble TREM2 Protect Against Alzheimer's Disease?","date":"2022","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35153729","citation_count":33,"is_preprint":false},{"pmid":"29889572","id":"PMC_29889572","title":"Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/29889572","citation_count":33,"is_preprint":false},{"pmid":"38453910","id":"PMC_38453910","title":"TREM2 deficiency impairs the energy metabolism of Schwann cells and exacerbates peripheral neurological deficits.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38453910","citation_count":30,"is_preprint":false},{"pmid":"36681358","id":"PMC_36681358","title":"Profiling TREM2 expression in amyotrophic lateral sclerosis.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36681358","citation_count":30,"is_preprint":false},{"pmid":"39956331","id":"PMC_39956331","title":"TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages.","date":"2025","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/39956331","citation_count":29,"is_preprint":false},{"pmid":"32826884","id":"PMC_32826884","title":"TMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32826884","citation_count":29,"is_preprint":false},{"pmid":"33881612","id":"PMC_33881612","title":"TREM2 expression in the brain and biological fluids in prion diseases.","date":"2021","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/33881612","citation_count":28,"is_preprint":false},{"pmid":"36318443","id":"PMC_36318443","title":"TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36318443","citation_count":27,"is_preprint":false},{"pmid":"37641212","id":"PMC_37641212","title":"TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages.","date":"2023","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/37641212","citation_count":27,"is_preprint":false},{"pmid":"37302170","id":"PMC_37302170","title":"TREM2, microglial and ischemic stroke.","date":"2023","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37302170","citation_count":25,"is_preprint":false},{"pmid":"36721205","id":"PMC_36721205","title":"Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology.","date":"2023","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/36721205","citation_count":25,"is_preprint":false},{"pmid":"35120968","id":"PMC_35120968","title":"Variant TREM2 Signaling in Alzheimer's Disease.","date":"2022","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35120968","citation_count":25,"is_preprint":false},{"pmid":"40695827","id":"PMC_40695827","title":"Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40695827","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49046,"output_tokens":9791,"usd":0.147002,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20044,"output_tokens":9190,"usd":0.164985,"stage2_stop_reason":"end_turn"},"total_usd":0.311987,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"TREM2 directly senses a broad array of anionic and zwitterionic lipids associated with fibrillar Aβ and damaged-neuron membranes, triggering intracellular protein tyrosine phosphorylation; the R47H mutation impairs this lipid detection. In the 5XFAD mouse model, TREM2 deficiency and haploinsufficiency augment Aβ accumulation due to failure of microglia to cluster around plaques and increased microglial apoptosis.\",\n      \"method\": \"Lipid-binding assays, 5XFAD mouse model (knockout and haploinsufficient), microglial survival and clustering assays, intracellular phosphorylation readouts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (lipid-binding assays, in vivo mouse model, phosphorylation assays) in a single rigorous study; foundational mechanism paper replicated broadly\",\n      \"pmids\": [\"25728668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TREM2 binds apolipoproteins (including APOE and CLU/APOJ) and lipoprotein particles (including LDL), identified by unbiased protein microarray screen. Disease-associated TREM2 mutations abolish or reduce this binding. TREM2 overexpression enhances uptake of LDL, CLU, and APOE; Trem2 knockout microglia show reduced internalization. Aβ-lipoprotein complexes are taken up by microglia in a TREM2-dependent manner, and uptake is reduced in macrophages from human TREM2-AD-variant carriers.\",\n      \"method\": \"Protein microarray screen, Co-IP/binding assays, overexpression and knockout cell assays, human macrophage uptake assay\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased screen followed by multiple orthogonal validation methods (pulldown, KO, human cells); replicated concept across multiple groups\",\n      \"pmids\": [\"27477018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM2 directly binds Aβ oligomers with nanomolar affinity; AD-associated TREM2 mutations reduce Aβ binding. TREM2 deficiency impairs Aβ degradation in primary microglia and mouse brain. Aβ-induced microglial responses (depolarization, K+ inward current, cytokine expression/secretion, migration, proliferation, apoptosis, morphological changes) are dependent on TREM2. Aβ enhances TREM2 interaction with its signaling adaptor DAP12, regulating downstream phosphorylation of SYK and GSK3β.\",\n      \"method\": \"Direct binding assay (nanomolar affinity measurement), primary microglial culture KO, mouse brain KO, Co-IP (TREM2–DAP12), phosphorylation assays (SYK, GSK3β), electrophysiology\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding assay, Co-IP, multiple functional readouts in primary cells and in vivo; rigorous single-study with multiple orthogonal methods\",\n      \"pmids\": [\"29518356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TREM2 undergoes ectodomain shedding by ADAM proteases (α-secretases). FTD/FTD-like syndrome-associated missense mutations reduce TREM2 maturation, abolish ADAM-mediated shedding, and impair phagocytic activity of TREM2-expressing cells. Reduced shedding results in virtual absence of soluble TREM2 in CSF and plasma.\",\n      \"method\": \"Cell-based maturation and shedding assays, phagocytosis assays, CSF/plasma protein measurement in patients, protease inhibitor experiments\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (shedding assay, phagocytosis, patient biofluid), mechanistically defined sheddase as ADAM protease\",\n      \"pmids\": [\"24990881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREM2 sustains microglial metabolic fitness by enabling mTOR signaling. TREM2-deficient microglia in AD mice and in AD patients carrying TREM2 risk variants display abundant autophagic vesicles linked to defective mTOR signaling, reduced ATP levels, and impaired biosynthetic pathways. Metabolic rescue via cyclocreatine (ATP analog) restores microglial clustering around plaques and decreases neuronal dystrophy in TREM2-deficient AD mice.\",\n      \"method\": \"Combined metabolomics and RNA-seq, mouse models (TREM2-deficient with amyloid pathology), in vitro rescue experiments, dietary cyclocreatine intervention, autophagic vesicle quantification\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — metabolomics + RNA-seq + in vivo rescue + human patient tissue, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"28802038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREM2 induces APOE signaling, mediating a switch from a homeostatic to a neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons. Targeting the TREM2-APOE pathway restored homeostatic microglial signature in ALS and AD mouse models and prevented neuronal loss in an acute neurodegeneration model.\",\n      \"method\": \"Mouse models of ALS, MS, AD (genetic and pharmacological targeting), transcriptional profiling, apoptotic neuron phagocytosis assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pathway epistasis in multiple disease models, transcriptional and functional rescue, replicated across disease contexts\",\n      \"pmids\": [\"28930663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD33 acts upstream of TREM2 in modulating microglial pathology in Alzheimer's disease. CD33 knockout attenuates Aβ pathology and improves cognition in 5xFAD mice, effects abrogated by additional TREM2 knockout. TREM2 knockout exacerbates Aβ pathology, and this cannot be rescued by CD33 knockout. RNA-seq shows phagocytosis- and signaling-related genes upregulated in 5xFAD;CD33-/- microglia depend on TREM2 presence.\",\n      \"method\": \"Genetic epistasis (double knockout mouse models), RNA-seq of sorted microglia, behavioral testing, amyloid burden quantification\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis with double KO, RNA-seq, multiple phenotypic readouts\",\n      \"pmids\": [\"31301936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the absence of functional TREM2, amyloid plaque seeding is increased due to reduced microglial clustering around newly seeded plaques and reduced plaque-associated ApoE deposition. Microglia are identified as one source of plaque-associated ApoE by microglia depletion experiments. Longitudinal amyloid PET demonstrates accelerated early amyloidogenesis in Trem2 loss-of-function mutants.\",\n      \"method\": \"Mouse models, microglia depletion experiments, proteomics, longitudinal amyloid small-animal PET, human brain tissue from TREM2 variant carriers\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (PET, proteomics, microglia depletion, human tissue validation)\",\n      \"pmids\": [\"30617257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TREM2 is a key transcriptional regulator of cholesterol transport and metabolism under chronic phagocytic challenge. TREM2-deficient microglia phagocytose myelin debris but fail to clear myelin cholesterol, resulting in cholesteryl ester (CE) accumulation. CE accumulation is also observed in APOE-deficient glial cells. This is replicated in myelin-treated TREM2-deficient murine macrophages and human iPSC-derived microglia and rescued by ACAT1 inhibitor and LXR agonist.\",\n      \"method\": \"Chronic demyelination mouse model, cell sorting with RNA-seq and lipidomics, TREM2-deficient murine macrophages, human iPSC-derived microglia, pharmacological rescue (ACAT1 inhibitor, LXR agonist)\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — RNA-seq, lipidomics, human iPSC microglia, pharmacological rescue, replicated across multiple model systems\",\n      \"pmids\": [\"31902528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2 interacts with TDP-43 protein, as demonstrated by mass spectrometry and surface plasmon resonance in vitro and in vivo, and in human ALS tissues. TREM2 deficiency impairs phagocytic clearance of pathological TDP-43 by microglia and enhances neuronal damage. Computationally identified regions within hTDP-43 interact with TREM2.\",\n      \"method\": \"Mass spectrometry, surface plasmon resonance (SPR), mouse viral/transgenic models, mass cytometry, human ALS tissue\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding measured by SPR, MS identification, in vivo validation, human tissue confirmation\",\n      \"pmids\": [\"34916658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2-dependent lipid droplet biogenesis is required for remyelination. Cholesterol esterification in microglia/macrophages is a necessary adaptive response to myelin debris uptake. TREM2-deficient mice cannot adapt to excess cholesterol, form fewer lipid droplets, and accumulate ER stress. Alleviating ER stress in TREM2-deficient mice restores lipid droplet biogenesis and resolves the innate immune response, enabling remyelination.\",\n      \"method\": \"Demyelinating injury mouse model, TREM2 KO mice, ER stress assays, lipid droplet quantification, pharmacological ER stress relief\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse model with mechanistic rescue (ER stress relief restores lipid droplets), multiple orthogonal readouts\",\n      \"pmids\": [\"34424266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Trem2 is a lipid-sensing receptor that controls lipid-associated macrophage (LAM) function in adipose tissue. Genetic ablation of Trem2 globally inhibits the downstream LAM transcriptional program, leading to adipocyte hypertrophy and systemic hypercholesterolemia, body fat accumulation, and glucose intolerance.\",\n      \"method\": \"Single-cell RNA sequencing (mouse and human), Trem2 genetic ablation, metabolic phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation with defined metabolic phenotypes, scRNA-seq in mouse and human, conserved across species\",\n      \"pmids\": [\"31257031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TREM2-expressing regulatory myeloid (Mreg) cells with high Arginase 1 activity accumulate intratumorally. Genetic ablation of Trem2 inhibits accumulation of these Mreg cells, leading to decreased dysfunctional CD8+ T cells and reduced tumor growth.\",\n      \"method\": \"INs-seq (integrated scRNA-seq + intracellular protein activity profiling), Trem2 genetic ablation in mouse tumor models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — novel integrated technology with genetic ablation and defined immunological phenotypes\",\n      \"pmids\": [\"32783915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The TREM2 transmembrane domain signals through the adaptor protein DAP12, which contains an ITAM motif. TREM2 ligation leads to Src family kinase activation, ITAM tyrosine phosphorylation, and recruitment of Syk and ZAP70 tyrosine kinases to initiate intracellular signaling cascade.\",\n      \"method\": \"Biochemical signaling assays, phosphorylation assays (referenced across multiple studies and review synthesis)\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — established across multiple labs but this paper is a review synthesis; original signaling mechanism replicated broadly\",\n      \"pmids\": [\"23459077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 mediates phagocytosis via Syk signaling in glioma-associated myeloid cells. TREM2+ myeloid cells display enhanced tumor uptake compared to TREM2- cells. TREM2 expression is positively associated with phagocytosis markers LYZ and CD163.\",\n      \"method\": \"In vivo phagocytosis tracking assay, in vitro phagocytosis assays, scRNA-seq of human gliomas, Syk inhibitor experiments, mouse glioma models\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic Syk link demonstrated in vitro with inhibitor, in vivo tracking assay, human scRNA-seq correlation\",\n      \"pmids\": [\"38237157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2 recognizes non-glycosylated mycolic acid (MA)-containing lipids from Mycobacterium cell walls via TREM2/DAP12-dependent but CARD9-independent signaling. This recruits iNOS-negative mycobacterium-permissive macrophages, opposing Mincle-FcRγ-CARD9-driven anti-mycobacterial immunity. TREM2 deletion enhances Mincle-induced macrophage activation and accelerates mycobacterial elimination, indicating TREM2-DAP12 counteracts anti-mycobacterial immunity.\",\n      \"method\": \"Macrophage activation assays, genetic KO (TREM2 and DAP12 KO mice), in vivo infection model, pathway epistasis (Mincle vs TREM2/DAP12)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis, KO mice, in vitro and in vivo infection models, multiple orthogonal readouts\",\n      \"pmids\": [\"33863908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TMEM59 (type I transmembrane protein) interacts with TREM2 (Co-IP). TREM2 overexpression promotes TMEM59 protein degradation, while Trem2-deficient microglia have elevated TMEM59 levels. Silencing TMEM59 rescues impaired survival, proliferation, migration, phagocytosis, and dysregulated autophagy and metabolism in Trem2-deficient microglia.\",\n      \"method\": \"Co-immunoprecipitation, overexpression and knockdown assays, Trem2-deficient microglia rescue experiments, autophagic flux assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP interaction plus functional rescue in Trem2-KO microglia, single lab\",\n      \"pmids\": [\"32826884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LILRB2, an inhibitory receptor bearing ITIM motifs, co-ligates with TREM2 on shared ligands (oligomeric Aβ and phosphatidylserine), leading to significant inhibition of TREM2 signaling. An antagonistic LILRB2 antibody (Ab29) prevents this inhibition, enhancing TREM2 signaling, microglial phagocytosis, migration, and cytokine responses in human iPSC-derived microglia and in vivo in 5XFAD mice.\",\n      \"method\": \"Human iPSC-derived microglia functional assays, antagonistic antibody blocking, in vivo 5XFAD stereotaxic grafting, phospho-signaling assays\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human iPSC microglia, in vivo assay, antibody functional rescue; single lab\",\n      \"pmids\": [\"35717259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Monoclonal antibody 4D9, targeting the stalk region epitope close to the TREM2 α-secretase cleavage site, reduces TREM2 shedding by ADAM10/17, stabilizes full-length TREM2 on the cell surface, and concomitantly activates phospho-SYK signaling. In vivo, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced the homeostatic marker in an AD mouse model.\",\n      \"method\": \"Antibody panel screening, shedding assays, phospho-SYK signaling assay, macrophage survival assay, myelin debris/Aβ phagocytosis in vitro, AD mouse model in vivo, CSF target engagement\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (shedding, signaling, phagocytosis, in vivo AD model, CSF biomarker), rigorous single study\",\n      \"pmids\": [\"32154671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Trem2 deletion in microglia enhances tau trafficking to endosomal/pre-exosomal compartments after internalization (without affecting uptake), increases tau content in microglial exosomes, and elevates tau-seeding capacity of secreted exosomes. In vivo, Trem2 KO enhances tau spreading from medial entorhinal cortex to hippocampus, impairing synaptic function and memory.\",\n      \"method\": \"AAV-P301L tau injection model (MEC), microfluidic tau dispersion assay, exosome isolation and tau FRET reporter seeding assay, proteomics, exosome inhibitor experiments, mouse KO\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, mechanistic exosome pathway established\",\n      \"pmids\": [\"36056435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Trem2 expression in microglia is required for maintaining normal neuronal bioenergetic profiles during postnatal development. In the absence of Trem2, CA1 (but not CA3) hippocampal pyramidal neurons display compromised energy metabolism, reduced mitochondrial mass, and abnormal organelle ultrastructure, accompanied by delayed neuronal maturation.\",\n      \"method\": \"Trem2 KO mouse model, single-cell/single-nucleus RNA sequencing, electron microscopy (mitochondrial ultrastructure), metabolic profiling of neurons by region\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with region-specific ultrastructural and transcriptional readouts, multiple orthogonal methods\",\n      \"pmids\": [\"38159572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 is required for efficient efferocytosis in macrophages. TREM2 deficiency reduces the ability of foamy macrophages to take up oxidized LDL. Mechanistically, TREM2-deficient macrophages fail to upregulate cholesterol efflux molecules, resulting in impaired proliferation and survival. A genome-wide CRISPR screen identified Trem2 as associated with foamy macrophage specification.\",\n      \"method\": \"Genome-wide CRISPR screen, single-cell RNA sequencing trajectory analysis, myeloid-specific Trem2 KO mouse, oxLDL uptake assay, cholesterol efflux assay, atherosclerosis mouse model\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR screen, myeloid-specific KO, functional lipid uptake/efflux assays, in vivo atherosclerosis model\",\n      \"pmids\": [\"38646596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 promotes macrophage efferocytosis and survival of lipid-laden macrophages in atherosclerosis. TREM2 deficiency increased necrotic core formation. TREM2 agonism decreased necrotic core formation. TREM2 is essential for the efferocytosis capacities of macrophages.\",\n      \"method\": \"Hematopoietic/global TREM2 KO mouse models, TREM2 agonist treatment, atherosclerosis mouse models, efferocytosis assays\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and pharmacological agonism, in vivo atherosclerosis model, efferocytosis assay\",\n      \"pmids\": [\"38974464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 promotes cholesterol uptake and foam cell formation by upregulating scavenger receptor CD36 expression. Mechanistically, TREM2 inhibits phosphorylation of p38 MAPK and PPARγ, thereby increasing PPARγ nuclear transcriptional activity and promoting CD36 transcription. Trem2-/-/ApoE-/- mice show reduced atherosclerotic lesion size and lipid burden.\",\n      \"method\": \"ApoE-/- and Trem2-/-/ApoE-/- double-KO mouse models, TREM2 overexpression in SMCs and macrophages, oxLDL uptake assays, p38/PPARγ phosphorylation assays, CD36 transcription assay\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway (p38-PPARγ-CD36) defined in cell culture, confirmed with double-KO in vivo; single lab\",\n      \"pmids\": [\"37133566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2-expressing macrophages in cardiac ischemia (TREM2hi Mac1 subset) actively scavenge cardiomyocyte-ejected dysfunctional mitochondria. Trem2 deficiency impairs Mac1 self-renewal, leading to defective elimination of damaged mitochondria, excessive cardiac inflammation, exacerbated dysfunction, and decreased survival.\",\n      \"method\": \"scRNA-seq, fate mapping, Trem2 KO mouse model of sepsis, macrophage transfer experiments, mitochondria scavenging assays\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — fate mapping + scRNA-seq + Trem2 KO + adoptive transfer, multiple orthogonal methods\",\n      \"pmids\": [\"36635449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In macrophages following efferocytosis, TREM2 decreases SLC25A53 transcription through the SYK-SMAD4 signaling pathway, impairing NAD+ transport into mitochondria and causing a breakpoint in the TCA cycle with increased itaconate production. Itaconate secreted by TREM2+ macrophages inhibits cardiomyocyte apoptosis and promotes fibroblast proliferation during MI repair.\",\n      \"method\": \"RNA-seq, protein interaction/molecular docking, targeted metabolomics (LC-MS), in vitro efferocytosis assays, macrophage-specific Trem2 KO mouse model of MI\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomics + RNA-seq + molecular docking; signaling pathway (SYK-SMAD4-SLC25A53) not fully validated by orthogonal methods in single paper\",\n      \"pmids\": [\"38182899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2+ macrophages suppress NK cell accumulation and cytolytic activity in lung cancer by modulating IL-18/IL-18BP decoy interactions and IL-15 production. Genetic deletion of Trem2 rescues NK cell accumulation and enables NK cell-mediated tumor regression.\",\n      \"method\": \"Murine lung adenocarcinoma model, Trem2 genetic deletion, cytokine profiling (IL-18, IL-18BP, IL-15), NK cell functional assays, TREM2 blockade synergy with NK cell-activating agent\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cytokine mechanism, multiple functional assays, pharmacological synergy, human tumor correlation\",\n      \"pmids\": [\"37081148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2+ TAMs in hepatocellular carcinoma secrete less CXCL9 but more galectin-1 compared to TREM2- TAMs. Galectin-1 promotes PD-L1 overexpression in vessel endothelial cells, impeding CD8+ T cell recruitment. TREM2 deficiency increases CD8+ T cell infiltration and enhances anti-PD-L1 blockade efficacy.\",\n      \"method\": \"scRNA-seq, in vitro co-culture, TREM2-KO mouse models (orthotopic and spontaneous HCC), immunofluorescence, flow cytometry\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway (TREM2→galectin-1→PD-L1→CD8+ T cell exclusion) validated in vitro and in two in vivo models\",\n      \"pmids\": [\"36889359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Soluble TREM2 (sTREM2) species (from both proteolytic shedding and alternatively spliced isoforms lacking transmembrane domain) inhibit long-term potentiation (LTP) in hippocampal brain slices, and this effect is abolished by the GABAA receptor antagonist picrotoxin.\",\n      \"method\": \"In vitro cleavage/secretion assays (HEK293T, HMC3), hippocampal LTP induction in brain slices, GABAA antagonist pharmacology, qPCR in AD patient post-mortem samples\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional LTP assay with pharmacological rescue, in vitro secretion validation; single lab\",\n      \"pmids\": [\"36805764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 is important for virus-induced IFNB induction through the cGAS-STING DNA-sensing pathway in microglia and for phagocytosis of HSV1-infected neurons. TREM2 augments STING signaling and activation of downstream targets TBK1 and IRF3. TREM2 depletion increased susceptibility to HSV1 infection in human microglia-neuron co-cultures and mouse brain.\",\n      \"method\": \"hiPSC-derived microglia with TREM2 depletion, IFNB induction assays, cGAS-STING/TBK1/IRF3 signaling assays, phagocytosis assay, mouse in vivo HSV1 infection\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human iPSC microglia + in vivo mouse, cGAS-STING pathway validation, single lab\",\n      \"pmids\": [\"37595041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM2 acts as a natural brake on TLR4-mediated proinflammatory signaling in hepatic macrophages and hepatic stellate cells. Trem2-deficient primary hepatic macrophages and stellate cells exhibit augmented TLR4-driven proinflammatory responses. Bone marrow transplantation experiments showed that both immune and resident cell TREM2 expression are required for full protection.\",\n      \"method\": \"Acute and chronic liver injury mouse models (Trem2 KO), primary hepatic macrophage isolation and TLR4 stimulation assays, bone marrow transplantation, ROS assays\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cell mechanistic assays + BM transplantation + in vivo KO; single lab\",\n      \"pmids\": [\"29374630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 deficiency impairs glycolytic flux and oxidative metabolism in Schwann cells, triggering mitochondrial damage and autophagy via AMPK activation and impaired PI3K-AKT-mTOR signaling. This energy crisis in TREM2-deficient Schwann cells impairs cell proliferation and axonal regeneration, exacerbating neurological deficits in a mouse model of acute motor axonal neuropathy.\",\n      \"method\": \"TREM2 KO Schwann cell energy metabolism assays (glycolysis, oxidative phosphorylation), metabolomics, AMPK/PI3K-AKT-mTOR pathway analysis, sciatic nerve model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomics + pathway analysis + in vivo mouse model; single lab, multiple methods\",\n      \"pmids\": [\"38453910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 functions as a key braking mechanism for the NLRP3/NF-κB/IL-1β inflammasome pathway in pancreatic macrophages, opposing microbial LPS as an activator of this pathway. TREM2 depletion orchestrates with LPS to trigger IL-1β upregulation and pathogenic inflammation, fueling PDAC development. IL-1β inhibition or microbiome ablation reverses the accelerated PDAC progression caused by TREM2 depletion.\",\n      \"method\": \"KPPC;Trem2-/- transgenic mouse model, scRNA-seq, IL-1β inhibition experiments, antibiotic-mediated microbiome ablation, pathway analysis (NLRP3/NF-κB/IL-1β)\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in spontaneous tumor model, scRNA-seq, pharmacological rescue; single lab\",\n      \"pmids\": [\"39956331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Microglia gravitate toward amyloid plaques surrounded by externalized phosphatidylserine (ePtdSer) from dystrophic neurons via TREM2. TREM2-mediated phagocytosis of Aβ is accelerated by ePtdSer. TREM2 loss-of-function (frameshift in exon 2) reduces phagocytic activity toward ePtdSer-positive Aβ plaques.\",\n      \"method\": \"2D/3D/4D co-culture systems with CRISPR-engineered TREM2 loss-of-function brain organoids/microglia/assembloids, APPNL-G-F/MAPT double knock-in mice, APOE4 iPSC lines\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR engineered organoid/assembloid system plus knock-in mouse model; single lab\",\n      \"pmids\": [\"38981007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2-IGF1 signaling axis regulates microglial functional and metabolic profiles, exerting neuroprotective effects in ischemic stroke. IGF1 is a major downstream molecule of Trem2. Overexpression of Igf1 and supplementation of cyclocreatine restore microglial glucometabolic levels and cellular functions even in the absence of Trem2.\",\n      \"method\": \"Single-nuclei RNA sequencing, microglial depletion (PLX3397) + repopulation, Trem2/Igf1 overexpression, cyclocreatine metabolic rescue, ischemic stroke mouse model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — snRNA-seq, pharmacological rescue, genetic manipulation; single lab with multiple methods\",\n      \"pmids\": [\"38151703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Trem2 H157Y knock-in mutation increases TREM2 shedding, elevating soluble TREM2 levels in brain and serum. This enhances synaptic plasticity and, in the presence of amyloid pathology, accelerates Aβ clearance and reduces amyloid burden and dystrophic neurites. Targeted mass spectrometry shows higher ratios of soluble to full-length TREM2-H157Y versus WT TREM2.\",\n      \"method\": \"CRISPR/Cas9 knock-in mouse model, targeted mass spectrometry, biochemical assays, hippocampal electrophysiology (LTP), in vivo microdialysis, immunofluorescence, cortical bulk RNA-seq\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — knock-in mouse, targeted MS (shedding quantification), electrophysiology, in vivo microdialysis, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"36721205\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TREM2 is a myeloid/microglial surface receptor that (1) senses lipids, lipoproteins (APOE, CLU), phosphatidylserine on damaged cells, Aβ oligomers, and TDP-43 via its extracellular immunoglobulin domain; (2) signals through the adaptor DAP12 via ITAM phosphorylation to activate Syk/ZAP70 and downstream mTOR, promoting microglial/macrophage survival, proliferation, migration, metabolic fitness (via mTOR), cholesterol handling, and phagocytic clearance; (3) is shed by ADAM10/17 α-secretases to produce a soluble form (sTREM2) that can inhibit LTP and modulate inflammation; (4) acts as a brake on TLR4 and NLRP3/NF-κB/IL-1β inflammatory signaling; (5) regulates lipid droplet biogenesis and cholesterol efflux under lipid-loading conditions; (6) drives APOE signaling to switch microglia from homeostatic to disease-associated states; and (7) disease-associated mutations (e.g., R47H) impair ligand sensing, receptor maturation, shedding, and downstream phagocytic function, increasing risk for Alzheimer's disease and other neurodegenerative conditions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TREM2 is a myeloid and microglial transmembrane immunoreceptor that couples sensing of lipids, lipoproteins, and damage-associated ligands to phagocytic, metabolic, and immune-regulatory programs [#0, #1]. Its extracellular immunoglobulin domain directly binds anionic and zwitterionic lipids exposed on damaged neuronal membranes [#0], apolipoproteins and lipoprotein particles including APOE, CLU/APOJ, and LDL [#1], oligomeric Aβ with nanomolar affinity [#2], externalized phosphatidylserine on dystrophic neurons [#33], and pathological TDP-43 [#9]; disease-associated mutations such as R47H reduce these binding events [#0, #1, #2]. Ligand engagement signals through the ITAM-bearing adaptor DAP12, driving Src-family-kinase phosphorylation and recruitment of Syk/ZAP70 [#13], a cascade enhanced by Aβ that controls downstream SYK and GSK3β phosphorylation [#2] and ultimately sustains microglial survival, clustering, and phagocytosis [#0, #14]. Downstream of this axis, TREM2 supports cellular metabolic fitness by enabling mTOR signaling and ATP production, with metabolic rescue restoring microglial plaque clustering [#4], and acts through an IGF1 axis to maintain microglial glucometabolism [#34]. TREM2 governs cholesterol handling under phagocytic load: it is required to clear myelin-derived cholesterol and prevent cholesteryl ester accumulation [#8] and to drive adaptive lipid droplet biogenesis that relieves ER stress and enables remyelination [#10], and it controls lipid-associated macrophage programs in adipose, atherosclerotic, and tumor tissues [#11, #21, #22]. It restrains inflammation, acting as a brake on TLR4 signaling [#30] and the NLRP3/NF-κB/IL-1β inflammasome [#32]. TREM2 is processed by ADAM α-secretases to release soluble TREM2; mutations that abolish shedding impair maturation and phagocytosis [#3], and soluble TREM2 inhibits hippocampal long-term potentiation through a GABAA-dependent mechanism [#28]. Through induction of APOE signaling, TREM2 drives the switch of microglia from a homeostatic to a disease-associated state during clearance of apoptotic neurons [#5]. In Alzheimer's pathology, loss of functional TREM2 reduces microglial clustering and plaque-associated ApoE, accelerating amyloid seeding [#7], and antibody stabilization of surface TREM2 or activating mutations that increase shedding can reduce amyloidogenesis [#18, #35]. Across cancers, TREM2-expressing regulatory and tumor-associated myeloid cells suppress CD8+ T-cell and NK-cell antitumor immunity [#12, #26, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that TREM2 is post-translationally processed and that pathogenic mutations act by impairing maturation and shedding, linking receptor biogenesis to phagocytic function and biofluid sTREM2 levels.\",\n      \"evidence\": \"Cell-based maturation/shedding and phagocytosis assays with patient CSF/plasma measurement\",\n      \"pmids\": [\"24990881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which ADAM protease predominates in vivo\", \"Functional role of the released soluble ectodomain not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified TREM2 as a direct lipid sensor for damaged-membrane and Aβ-associated lipids whose engagement triggers tyrosine phosphorylation and is required for microglial survival and plaque clustering, providing the first ligand-driven mechanism for AD risk.\",\n      \"evidence\": \"Lipid-binding assays plus 5XFAD knockout/haploinsufficient mouse microglial clustering and survival readouts\",\n      \"pmids\": [\"25728668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the precise lipid headgroup specificity\", \"How lipid binding is mechanically transduced to DAP12 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed TREM2 binds apolipoproteins and lipoprotein particles and mediates their uptake, connecting receptor ligand recognition to lipid/lipoprotein clearance and explaining APOE/CLU-related risk convergence.\",\n      \"evidence\": \"Unbiased protein microarray screen with pulldown, overexpression/KO uptake assays, and human variant-carrier macrophages\",\n      \"pmids\": [\"27477018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinities and lipidation-state dependence not fully quantified\", \"Intracellular routing of internalized lipoproteins not traced\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked TREM2 signaling to microglial bioenergetics by showing it sustains mTOR-dependent metabolic fitness, and demonstrated that metabolic supplementation restores plaque clustering, reframing TREM2 dysfunction as a metabolic deficit.\",\n      \"evidence\": \"Metabolomics + RNA-seq, TREM2-deficient amyloid mice, human variant tissue, and dietary cyclocreatine rescue\",\n      \"pmids\": [\"28802038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The signaling steps from DAP12/Syk to mTOR not delineated\", \"Whether metabolic rescue translates to humans untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a TREM2-APOE axis that switches microglia from homeostatic to neurodegenerative states after engulfing apoptotic neurons, establishing TREM2 as a master regulator of disease-associated microglial identity.\",\n      \"evidence\": \"Transcriptional profiling and genetic/pharmacological targeting across ALS, MS, and AD mouse models\",\n      \"pmids\": [\"28930663\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direction of causality between TREM2 and APOE induction not fully resolved\", \"Transcription factors executing the state switch not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated direct nanomolar Aβ-oligomer binding and that Aβ enhances TREM2-DAP12 coupling and SYK/GSK3β phosphorylation, showing Aβ itself is an activating ligand controlling microglial responses and degradation.\",\n      \"evidence\": \"Direct binding assays, Co-IP, phosphorylation and electrophysiology in primary microglia and mouse brain KO\",\n      \"pmids\": [\"29518356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether monomeric vs oligomeric Aβ differ mechanistically not fully dissected\", \"Relationship between Aβ binding and lipid/lipoprotein binding sites unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established TREM2 as a brake on TLR4-driven proinflammatory signaling in liver, extending its function beyond brain to a general anti-inflammatory rheostat in tissue macrophages.\",\n      \"evidence\": \"Trem2 KO liver injury models, primary hepatic macrophage TLR4 stimulation, and bone marrow transplantation\",\n      \"pmids\": [\"29374630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which TREM2 antagonizes TLR4 not defined\", \"Single lab; reciprocal signaling crosstalk not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed TREM2 within a CD33-TREM2 epistatic hierarchy in AD, showing CD33's protective effects require functional TREM2 and that TREM2 loss cannot be compensated, defining pathway order among AD myeloid risk genes.\",\n      \"evidence\": \"Double-knockout mouse genetic epistasis with RNA-seq, behavior, and amyloid quantification\",\n      \"pmids\": [\"31301936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical link between CD33 and TREM2 signaling not established\", \"Whether interaction is direct or convergent unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that loss of TREM2 function accelerates early amyloid seeding via reduced microglial clustering and plaque-associated ApoE deposition, identifying microglia as an ApoE source shaping plaque formation.\",\n      \"evidence\": \"Longitudinal amyloid PET, proteomics, microglia depletion, and human variant-carrier tissue\",\n      \"pmids\": [\"30617257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which microglial ApoE limits seeding not fully defined\", \"Temporal window of intervention unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Generalized TREM2 as the controller of a lipid-associated macrophage program governing systemic metabolism, linking its loss to adipocyte hypertrophy, hypercholesterolemia, and glucose intolerance.\",\n      \"evidence\": \"Single-cell RNA-seq in mouse and human with Trem2 ablation and metabolic phenotyping\",\n      \"pmids\": [\"31257031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand triggering the LAM program in adipose not identified\", \"Causal step from TREM2 signaling to transcriptional LAM program unmapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined TREM2 as a transcriptional regulator of cholesterol transport under chronic phagocytic challenge, with loss causing cholesteryl ester accumulation rescuable by ACAT1 inhibition or LXR agonism.\",\n      \"evidence\": \"Chronic demyelination model, RNA-seq/lipidomics, murine and human iPSC microglia, pharmacological rescue\",\n      \"pmids\": [\"31902528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets controlling efflux not enumerated\", \"Link from surface receptor to nuclear lipid programs incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Consolidated the canonical TREM2 signaling module: transmembrane association with ITAM-bearing DAP12, Src-family kinase activation, and Syk/ZAP70 recruitment, providing the proximal signaling framework.\",\n      \"evidence\": \"Review synthesis of biochemical signaling and phosphorylation assays across labs\",\n      \"pmids\": [\"23459077\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review synthesis rather than primary mechanism in one system\", \"Quantitative stoichiometry of TREM2-DAP12 not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified TMEM59 as a TREM2-interacting protein whose degradation depends on TREM2 and whose silencing rescues multiple Trem2-deficient phenotypes, nominating a downstream effector node.\",\n      \"evidence\": \"Co-IP, overexpression/knockdown, and rescue in Trem2-deficient microglia\",\n      \"pmids\": [\"32826884\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without structural validation of the interaction\", \"Mechanism of TREM2-driven TMEM59 degradation not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated antibody stabilization of surface TREM2 by blocking shedding near the cleavage site activates phospho-SYK signaling and reduces amyloidogenesis, validating shedding control as a therapeutic lever.\",\n      \"evidence\": \"Antibody 4D9 shedding/signaling/phagocytosis assays plus AD mouse model with CSF target engagement\",\n      \"pmids\": [\"32154671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether surface stabilization or epitope agonism dominates not separated\", \"Long-term consequences of chronic TREM2 activation untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed an immunosuppressive role for TREM2+ regulatory myeloid cells in tumors, where Trem2 ablation reduces their accumulation and restores antitumor CD8+ T-cell function.\",\n      \"evidence\": \"Integrated scRNA-seq/protein-activity profiling (INs-seq) with Trem2 ablation in tumor models\",\n      \"pmids\": [\"32783915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand driving intratumoral Mreg differentiation unidentified\", \"Whether effect requires DAP12 signaling not tested here\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed TREM2 recognizes mycobacterial mycolic-acid lipids and that TREM2-DAP12 counteracts protective Mincle-CARD9 immunity, demonstrating context-dependent immunosuppression in infection.\",\n      \"evidence\": \"Macrophage activation assays, TREM2 and DAP12 KO mice, and pathway epistasis with Mincle\",\n      \"pmids\": [\"33863908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of mycolic acid recognition not resolved\", \"How TREM2 and Mincle outputs are integrated in one cell unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established TREM2-dependent lipid droplet biogenesis as an adaptive response that relieves ER stress and enables remyelination, mechanistically connecting lipid storage to inflammation resolution.\",\n      \"evidence\": \"Demyelinating injury KO mice with ER stress assays, lipid droplet quantification, and pharmacological ER stress relief\",\n      \"pmids\": [\"34424266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling link from TREM2 to droplet biogenesis machinery not defined\", \"Relationship to the cholesterol efflux pathway not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified TDP-43 as a TREM2 ligand and showed TREM2 is required for microglial clearance of pathological TDP-43, extending TREM2 ligand sensing to a major ALS/FTD aggregate.\",\n      \"evidence\": \"Mass spectrometry, SPR binding, mouse models, and human ALS tissue\",\n      \"pmids\": [\"34916658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface mapped only computationally\", \"Whether clearance proceeds via canonical DAP12 signaling untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed TREM2 restrains tau propagation by limiting trafficking of internalized tau into exosomes, revealing a degradation-versus-spreading checkpoint distinct from uptake.\",\n      \"evidence\": \"AAV-tau model, exosome FRET seeding assays, proteomics, and Trem2 KO spreading studies\",\n      \"pmids\": [\"36056435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery diverting tau to exosomes vs degradation unknown\", \"Whether TREM2 acts on tau directly or via metabolic state unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a TREM2-IGF1 axis maintaining microglial glucometabolism with neuroprotective effects in stroke, where IGF1 overexpression or cyclocreatine rescues Trem2-deficient deficits.\",\n      \"evidence\": \"snRNA-seq, microglial depletion/repopulation, genetic and metabolic rescue in ischemic stroke mice\",\n      \"pmids\": [\"38151703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional control of Igf1 by TREM2 signaling not proven\", \"Single lab; human relevance untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed TREM2 in microglia is required for normal neuronal bioenergetics during postnatal development, revealing a non-cell-autonomous role in neuronal maturation independent of disease.\",\n      \"evidence\": \"Trem2 KO mice with region-specific single-cell RNA-seq, electron microscopy, and neuronal metabolic profiling\",\n      \"pmids\": [\"38159572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Microglia-to-neuron signal mediating bioenergetic support unidentified\", \"Why CA1 but not CA3 neurons are affected unexplained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated soluble TREM2 species inhibit hippocampal LTP through a GABAA-dependent mechanism, assigning a distinct gain-of-function activity to the shed/spliced ectodomain.\",\n      \"evidence\": \"In vitro secretion assays, hippocampal LTP recordings with picrotoxin, and AD post-mortem qPCR\",\n      \"pmids\": [\"36805764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"sTREM2 receptor/binding partner mediating GABAA effect unknown\", \"Single lab; in vivo physiological relevance not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed TREM2 augments antiviral cGAS-STING-TBK1-IRF3 signaling and phagocytosis of infected neurons, adding an antiviral arm to TREM2 myeloid function.\",\n      \"evidence\": \"hiPSC microglia with TREM2 depletion, IFNB and STING-pathway assays, and in vivo HSV1 infection\",\n      \"pmids\": [\"37595041\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How TREM2 connects to the cytosolic DNA-sensing pathway not defined\", \"Single lab; specificity for DNA viruses untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed an activating H157Y knock-in increases shedding and elevated soluble TREM2, enhancing synaptic plasticity and accelerating amyloid clearance, demonstrating that increased shedding can be beneficial in amyloid context.\",\n      \"evidence\": \"CRISPR knock-in mice, targeted MS shedding quantification, LTP, and in vivo microdialysis\",\n      \"pmids\": [\"36721205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with sTREM2-mediated LTP inhibition not resolved\", \"Whether benefit reflects full-length loss or soluble gain unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established TREM2 as essential for macrophage efferocytosis and cholesterol efflux in atherosclerosis, with deficiency enlarging necrotic cores and agonism reducing them, broadening cardiovascular relevance.\",\n      \"evidence\": \"Genome-wide CRISPR screen, myeloid-specific and global KO, oxLDL uptake/efflux assays, and agonist treatment in atherosclerosis models\",\n      \"pmids\": [\"38646596\", \"38974464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional effectors of efflux downstream of TREM2 not enumerated\", \"Whether efferocytosis defect is metabolic or signaling-driven unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a TREM2-p38/PPARγ-CD36 pathway promoting cholesterol uptake and foam cell formation, providing a transcriptional mechanism for TREM2-driven lipid loading.\",\n      \"evidence\": \"ApoE-/- and Trem2-/-/ApoE-/- mice, overexpression, oxLDL uptake, and p38/PPARγ/CD36 assays\",\n      \"pmids\": [\"37133566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; pathway not validated by orthogonal genetics\", \"Apparent tension with protective efferocytosis role not reconciled\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed TREM2+ tumor-associated macrophages suppress NK and CD8+ T-cell antitumor immunity via cytokine decoy and galectin-1/PD-L1 mechanisms, nominating TREM2 as an immunotherapy target across cancers.\",\n      \"evidence\": \"scRNA-seq, co-culture, Trem2 KO tumor models, cytokine profiling, and checkpoint-blockade synergy\",\n      \"pmids\": [\"37081148\", \"36889359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether immunosuppression requires TREM2 ligand sensing untested\", \"Mechanism linking TREM2 to galectin-1/IL-18BP output not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed TREM2+ macrophages scavenge ejected dysfunctional mitochondria and that TREM2 supports their self-renewal, protecting against cardiac inflammation and dysfunction.\",\n      \"evidence\": \"scRNA-seq, fate mapping, Trem2 KO cardiac injury, and adoptive transfer with mitochondria scavenging assays\",\n      \"pmids\": [\"36635449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-ligand basis of mitochondrial recognition not defined\", \"Link to canonical DAP12/Syk signaling not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked post-efferocytosis TREM2-SYK-SMAD4 signaling to SLC25A53 repression, mitochondrial NAD+ limitation, and itaconate secretion that supports cardiac repair, connecting TREM2 to immunometabolite output.\",\n      \"evidence\": \"RNA-seq, targeted metabolomics, molecular docking, and macrophage-specific Trem2 KO MI model\",\n      \"pmids\": [\"38182899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SYK-SMAD4-SLC25A53 axis not validated by orthogonal methods\", \"Direct TREM2 control over SMAD4 not demonstrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established TREM2 as a brake on the NLRP3/NF-κB/IL-1β inflammasome opposing LPS, with loss accelerating pancreatic tumor progression reversible by IL-1β inhibition or microbiome ablation.\",\n      \"evidence\": \"KPPC;Trem2-/- mice, scRNA-seq, IL-1β inhibition, and antibiotic microbiome ablation\",\n      \"pmids\": [\"39956331\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of inflammasome restraint not defined\", \"Single lab; whether brake is direct or metabolic unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed externalized phosphatidylserine on dystrophic neurons guides TREM2-mediated microglial recruitment and accelerates Aβ phagocytosis, with loss-of-function reducing clearance of ePtdSer-positive plaques.\",\n      \"evidence\": \"CRISPR loss-of-function organoids/assembloids, knock-in mice, and APOE4 iPSC lines in multidimensional co-cultures\",\n      \"pmids\": [\"38981007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; direct PtdSer-TREM2 binding affinity not quantified here\", \"How ePtdSer and Aβ co-signals are integrated unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TREM2's diverse ligand inputs are integrated at the receptor to produce distinct context-specific transcriptional and metabolic outputs, and how soluble TREM2's beneficial versus inhibitory activities are reconciled, remain unresolved.\",\n      \"evidence\": \"No single discovery in the corpus unifies ligand integration with output specification or sTREM2 dual roles\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model linking specific ligands to specific signaling outputs\", \"sTREM2 receptor and its physiological role undefined\", \"Mechanism converting surface signaling into nuclear lipid/metabolic programs incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [1, 21, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [30, 32]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 13, 18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 28, 35]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 15, 30, 32]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 8, 11, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 13, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 5, 7, 26]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 2, 14, 21, 22]}\n    ],\n    \"complexes\": [\"TREM2-DAP12 receptor-adaptor complex\"],\n    \"partners\": [\"DAP12\", \"APOE\", \"CLU\", \"TDP-43\", \"TMEM59\", \"LILRB2\", \"SYK\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}